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Introduction 
The Department of Health (DH) asked the National Institute for Health and 
Clinical Excellence (NICE or the Institute) to produce public health guidance 
on smoking cessation services. 
This guidance supersedes ‘Guidance on the use of nicotine replacement 
therapy (NRT) and bupropion for smoking cessation’ (NICE technology 
appraisal guidance 39). It cross-references and is consistent with ‘Brief 
interventions and referral for smoking cessation in primary care and other 
settings’ (NICE public health guidance 1), ‘Workplace health promotion: how 
to help employees to stop smoking’ (NICE public health guidance 5) and 
‘Varenicline for smoking cessation’ (NICE technology appraisal guidance 
123). 
The guidance is for NHS and other professionals who have a direct or indirect 
role in – and responsibility for – smoking cessation services. This includes 
those working in local authorities and the community, voluntary and private 
sectors. It may also be of interest to members of the public who wish to give 
up smoking, including specific groups such as pregnant women and mothers 
of young children. 
The Programme Development Group (PDG) has considered five reviews of 
the evidence on smoking cessation services, two reviews on nicotine 
replacement therapy, an expert paper, an economic appraisal, stakeholder 
comments and the results of fieldwork in developing these recommendations. 
Details of membership of the PDG are given in appendix A. The methods 
used to develop the guidance are summarised in appendix B. Supporting 
documents used in the preparation of this document are listed in appendix E. 
Full details of the evidence collated, including fieldwork data and activities and 
stakeholder comments, are available on the NICE website, along with a list of 
the stakeholders involved and the Institute’s supporting process and methods 
manuals. The website address is: www.nice.org.uk  
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This guidance was developed using the NICE public health programme 
process. 
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1 Key priorities  
This section lists the four recommendations that have been identified as key 
priorities for implementation, on the basis of the following criteria:  
impact on health inequalities  
impact on health of the target population 
cost effectiveness 
balance of risks and benefits. 
ease of implementation  
speed of impact 
Smoking cessation services 
Recommendation 1  
Who is the target population? 
Everyone who smokes or uses any other form of tobacco.  
Who should take action? 
• Primary care trusts (PCTs), strategic health authorities (SHAs). 
• Commissioners of publicly funded smoking cessation services. 
What action should they take? 
• Determine the characteristics of the local population of people who smoke 
or use other forms of tobacco. Determine the prevalence of all forms of 
tobacco use locally. 
• Ensure NHS Stop Smoking Services target minority ethnic and 
socioeconomically disadvantaged communities in the local population.  
• Ensure NHS Stop Smoking Services provide a good service by maintaining 
adequate staffing levels, including a full-time coordinator (or the 
equivalent). 
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• Set realistic performance targets for both the number of people using the 
service and the proportion who successfully quit smoking. These targets 
should reflect the demographics of the local population. Services should: 
− aim to treat at least 5% of the estimated local population of 
people who smoke or use tobacco in any form each year 
− aim for a success rate of at least 35% at 4 weeks, validated 
by carbon monoxide monitoring. This figure should be based 
on all those who start treatment, with success defined as not 
having smoked in the third and fourth week after the quit date. 
Success should be validated by a CO monitor reading of less 
than 10 ppm at the 4-week point. This does not imply that 
treatment should stop at 4 weeks. 
• Audit performance data routinely and independently and make the results 
publicly available. Audits should also be carried out on exceptional results – 
4-week quit rates lower than 35% or above 70% – to determine the reasons 
for unusual performance, and to help identify best practice and ensure it is 
being followed. 
• Establish links between contraceptive services, fertility clinics and  
ante- and postnatal services. These links should ensure health 
professionals use the many opportunities available to them (at various 
stages of the woman’s life) to offer smoking advice or referral to a specialist 
service, where appropriate.   
(See also NICE public health guidance 1 on smoking cessation in primary 
care and other settings at: www.nice.org.uk/PHI001) 
Recommendation 2 
Who is the target population? 
Everyone who smokes or uses tobacco in any other form. 
Who should take action? 
Managers and providers of NHS Stop Smoking Services.  
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What action should they take? 
• Offer behavioural counselling, group therapy, pharmacotherapy or a 
combination of treatments that have been proven to be effective (see the 
list at the start of section 4). 
• Ensure clients receive behavioural support from a person who has had 
training and supervision that complies with the ‘Standard for training in 
smoking cessation treatments’ or its updates 
(www.nice.org.uk/page.aspx?o=502591).  
• Provide tailored advice, counselling and support, particularly to clients from 
minority ethnic and disadvantaged groups. Provide services in the 
language chosen by clients, wherever possible.  
• Ensure the local NHS Stop Smoking Service aims to treat minority ethnic 
and disadvantaged groups at least in proportion to their representation in 
the local population of tobacco users.  
(See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001) 
Pharmocotherapies 
Recommendation 4 
Who is the target population? 
People who want to stop smoking. 
Who should take action? 
Healthcare professionals who advise on, or prescribe, nicotine replacement 
therapy (NRT), varenicline or bupropion.  
What action should they take? 
• Offer NRT, varenicline or bupropion, as appropriate, to people who are 
planning to stop smoking.  
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• Offer advice, encouragement and support, including referral to the NHS 
Stop Smoking Service, to help people in their attempt to quit.  
• NRT, varenicline or bupropion should normally be prescribed as part of an 
abstinent-contingent treatment, in which the smoker makes a commitment 
to stop smoking on or before a particular date (target stop date). The 
prescription of NRT, varenicline or bupropion should be sufficient to last 
only until 2 weeks after the target stop date. Normally, this will be after 2 
weeks of NRT therapy, and 3–4 weeks for varenicline and bupropion, to 
allow for the different methods of administration and mode of action. 
Subsequent prescriptions should be given only to people who have 
demonstrated, on re-assessment, that their quit attempt is continuing.  
• Explain the risks and benefits of using NRT to young people aged from 12 
to 17, pregnant or breastfeeding women, and people who have unstable 
cardiovascular disorders. To maximise the benefits of NRT, people in these 
groups should also be strongly encouraged to use behavioural support in 
their quit attempt.  
• Neither varenicline or bupropion should be offered to young people under 
18 nor to pregnant or breastfeeding women.  
• Varenicline or bupropion may be offered to people with unstable 
cardiovascular disorders, subject to clinical judgement.  
• If a smoker’s attempt to quit is unsuccessful using NRT, varenicline or 
bupropion, do not offer a repeat prescription within 6 months unless special 
circumstances have hampered the person’s initial attempt to stop smoking, 
when it may be reasonable to try again sooner.  
• Do not offer NRT, varenicline or bupropion in any combination. 
• Consider offering a combination of nicotine patches and another form of 
NRT (such as gum, inhalator, lozenge or nasal spray) to people who show 
a high level of dependence on nicotine or who have found single forms of 
NRT inadequate in the past. 
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• Do not favour one medication over another. The clinician and patient 
should choose the one that seems most likely to succeed.  
• When deciding which therapies to use and in which order, discuss the 
options with the client and take into account: 
− whether a first offer of referral to the NHS Stop Smoking 
Service has been made 
− contra-indications and the potential for adverse effects  
− the client’s personal preferences 
− the availability of appropriate counselling or support  
− the likelihood that the client will follow the course of treatment 
− their previous experience of smoking cessation aids.  
This supersedes NICE technology appraisal guidance 39 on NRT and 
bupropion. (See also NICE technology appraisal guidance 123 on varenicline 
at www.nice.org.uk/TA123) 
Pregnancy 
Recommendation 8 
Who is the target population? 
Women who smoke and who are either pregnant or are planning a pregnancy, 
and their partners and family members who smoke. 
Who should take action? 
All those responsible for providing health and support services for pregnant 
women, for those wishing to become pregnant, and for their partners. This 
includes: those working in fertility clinics, midwives, GPs, dentists, hospital 
and community pharmacists, and those working in children’s centres, 
voluntary organisations and occupational health services.  
What action should they take? 
• At the first contact with the woman, discuss her smoking status, provide 
information about the risks of smoking to the unborn child and the hazards 
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of exposure to secondhand smoke. Address any concerns she and her 
partner or family may have about stopping smoking.  
• Offer personalised information, advice and support on how to stop 
smoking. Encourage pregnant women to use local NHS Stop Smoking 
Services and the NHS Pregnancy Smoking Helpline by providing details on 
when, where and how to access them. Consider visiting pregnant women 
at home if it is difficult for them to attend specialist services.    
• Monitor smoking status and offer smoking cessation advice, 
encouragement and support throughout the pregnancy and beyond.  
• Discuss the risks and benefits of NRT with pregnant women who smoke, 
particularly those who do not wish to accept the offer of help from the NHS 
Stop Smoking Service. If a woman expresses a clear wish to receive NRT, 
use professional judgement when deciding whether to offer a prescription. 
• Advise pregnant women using nicotine patches to remove them before 
going to bed. 
This supersedes NICE technology appraisal guidance 39 on NRT and 
bupropion. (See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001) 
2 Public health need and practice 
Smoking remains the main cause of preventable morbidity and premature 
death in England, leading to an estimated annual average of 86,500 deaths 
between 1998 and 2002 (Twigg et al. 2004). It is the primary reason for the 
gap in healthy life expectancy between rich and poor. Among men, smoking is 
responsible for over half the excess risk of premature death between the 
social classes (Jarvis and Wardle 1999).  
A wide range of diseases and conditions are caused by cigarette smoking, 
including cancers, respiratory diseases, coronary heart and other circulatory 
diseases, stomach and duodenal ulcers, erectile dysfunction and infertility, 
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osteoporosis, cataracts, age-related macular degeneration and periodontitis 
(US Department of Health and Human Services 2004). Following surgery, 
smoking contributes to lower survival rates, delayed wound healing and post-
operative respiratory complications (US Department of Health and Human 
Services 2004).  
Women who smoke during pregnancy have a substantially higher risk of 
spontaneous abortion (miscarriage) than those who do not smoke. Smoking 
can also cause complications in pregnancy and labour, including ectopic 
pregnancy, bleeding during pregnancy, premature detachment of the placenta 
and premature rupture of the membranes (British Medical Association 2004).  
The health risks for babies are substantial. Those born to women who smoke 
are on average 200–250g lighter than babies born to  mothers who do not 
smoke (British Medical Association 2004); the more cigarettes smoked, the 
greater the probable reduction in birth weight. This can increase the risk of 
death and disease in childhood: smoking in pregnancy increases infant 
mortality by about 40% (DH 2007) and more than a quarter of the risk of 
sudden unexpected death in infancy is attributable to smoking (British Medical 
Association 2004).  
Breathing secondhand smoke (‘passive smoking’) can affect the health of 
people who do not smoke. For example, it can exacerbate respiratory 
symptoms and trigger asthma attacks. Longer term, it increases the risk of 
lung cancer, respiratory illnesses (especially asthma), heart disease and 
stroke (International Agency for Research on Cancer 2002; Scientific 
Committee on Tobacco and Health 2004; US Environmental Protection 
Agency 1993).  Exposure to secondhand smoke in pregnancy can reduce 
fetal growth and increase the risk of preterm birth (British Medical Association 
2004).  
Smoking is estimated to cost the NHS £1.5 billion a year (Parrott et al. 1998). 
This estimate does not include other costs to government such as payment of 
sickness or invalidity benefits. Nor does it include the costs to industry or to 
individuals who smoke. 
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In England about 24% of people aged 16 and over in 2006 smoked (Lader 
2007). Although smoking prevalence has dropped sharply since the 1970s, 
the decline has been much slower in the last decade. Recent estimates 
suggest that it is dropping by 0.4% a year (Jarvis 2003).  
The government target to reduce smoking prevalence among manual1
Smoking prevalence is also high among some minority ethnic groups (Erens 
et al. 2000). Among all groups, it is age-related. For example, among 
pregnant women smoking prevalence is highest for those under 35 (Penn and 
Owen 2002; Sproston and Primatesta 2004); and 45% of mothers aged under 
20 smoke during their pregnancy (DH 2007). Among adults aged 16 and over, 
smoking prevalence for men was highest among those aged 20–34 (43% for 
both 20–24 year olds and 25–34 year olds) and for women highest among 
those aged 25–34 (29%) (Lader 2007).  
 
working groups to 26% or less by 2010 will be challenging (HM Treasury 
2004). In England in 2005 about 29% of those in routine or manual 
occupations smoked (Goddard 2006).  
This guidance is aimed at those working in the NHS, local authorities, other 
public sector organisations, and the community, voluntary and private sectors 
who have a direct or indirect role or responsibility for smoking cessation. 
 
                                                 
1 From 2001, the classification system used to describe social class based on occupation was 
replaced by the National Statistics Socio-economic Classification (NS-SEC). ‘Manual’ 
households are now described as ‘routine and manual’ households: the phrase ‘routine and 
manual’ is now used for PSA targets. 
www.statistics.gov.uk/methods_quality/ns_sec/default.asp 
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3 Considerations 
The PDG took account of a number of factors and issues in making the 
recommendations. 
3.1 Social inequalities in tobacco use make a significant contribution to 
inequalities in health. Interventions that are effective in reducing 
social inequalities in tobacco use are therefore central to the 
government’s public health strategy and to the broader goal of 
promoting health equity. 
3.2 Smoking cessation interventions tailored for people from minority 
ethnic or disadvantaged groups may be slightly more effective than 
generic interventions aimed at these groups. However, it is unlikely 
that tailored interventions alone would make a large impression on 
the social gradient in smoking prevalence. It is important to ensure 
that NHS Stop Smoking Services are easily accessible by people 
from these groups and that they are encouraged to use them.  
3.3 Learning from social marketing theory suggests that efforts to combat 
smoking should be multifaceted. Media campaigns should be 
coordinated with other activities such as smoking cessation services, 
policy change and school interventions, and all stakeholders should 
be involved. Above all, the needs of target groups should be put first. 
Initiatives should aim to bring about sustained individual and social 
change, which takes time. It is important to take a strategic 
perspective, developing relationships with target groups and 
stakeholders and encouraging full community engagement.  
3.4 Community pharmacies serve local communities and have the 
potential to reach and treat large numbers of people who use 
tobacco. They are able to meet the needs of minority ethnic and 
disadvantaged groups and those who may have difficulty accessing 
other community services. Community pharmacies are contractually 
obliged to take part each year in up to six public campaigns 
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organised by primary care trusts (PCTs), so they also have an 
important role to play in local education and communication 
campaigns.   
3.5 NHS Stop Smoking Services have helped large numbers of people to 
quit smoking. However, smoking cessation rates are still lower 
among people in routine and manual groups than among those in 
higher socioeconomic groups. This suggests that some groups face 
social and economic barriers that may inhibit their ability to quit. 
Reducing smoking prevalence among people in routine and manual 
groups, some minority ethnic groups and disadvantaged communities 
will help reduce health inequalities more than any other public health 
measure.  
3.6 Pregnant women in routine and manual groups and those aged 20 or 
under may need additional support to give up smoking. By registering 
with their midwife or health visitor for Healthy Start, pregnant women 
and mothers of children under 4 years who are eligible for certain 
benefits, and all pregnant women under 18 years, can obtain food 
vouchers and vitamin supplements. When women register for Healthy 
Start, professionals are encouraged to provide health and lifestyle 
advice and to continue advising during pregnancy and beyond. The 
PDG believes health professionals should use Healthy Start 
registration as an opportunity to offer information, advice and support 
on stopping smoking, including details of when, where and how to 
use local NHS Stop Smoking Services. The emphasis must be on 
quitting and not on cutting down. 
3.7 It may take many attempts before people can successfully quit 
smoking and they need to be encouraged in all of these endeavours. 
However, the interval between quit attempts needs careful discussion 
with the client to minimise the risk of a previous failure adversely 
affecting the next attempt to stop smoking. 
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3.8 Many people attempt to quit smoking using a variety of methods. The 
PDG believes quitting should always be encouraged, but that only 
proven treatments should be provided by the NHS. Treatments that 
have not been rigorously evaluated and found to be effective should 
not be available through the NHS. The PDG cannot recommend that 
the NHS should provide: 
− ‘Rapid smoking’– although there is good evidence that this 
form of aversion therapy improves abstinence rates, its 
practice is not now recommended because it conflicts with 
smokefree regulations and the PDG was also concerned 
about exposing practitioners to clients’ tobacco smoke.   
− Acupuncture, acupressure, laser therapy and electro-
stimulation – there is evidence that these techniques do not 
improve long-term abstinence rates more than a placebo.  
− Hypnotherapy – there is evidence that hypnotherapy does not 
improve long-term abstinence rates more than other 
interventions that give the same amount of time and attention 
to the participant, such as individual counselling.  
− Glucose – although there is some evidence that glucose may 
reduce the desire to smoke and increase cessation rates if 
taken when using a nicotine patch, the evidence is not robust.  
3.9 The PDG examined two other means to help people stop smoking: 
cytisine and Allen Carr’s Easyway method. There is not enough 
evidence from well-conducted studies to recommend these aids and 
the PDG thought it appropriate to call for further research on both.  
3.10 In 2005, the Medicines and Healthcare Regulatory Authority (MHRA) 
undertook a review of the licensing arrangements for nicotine 
replacement therapy (NRT). The changes were: 
• all forms of NRT can be used for young people aged 12–17 who 
smoke 
• NRT can be used by pregnant women who smoke 
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• NRT can be used by breastfeeding mothers who smoke 
• all forms of NRT can be used by people with cardiovascular 
disease 
• more than one form of NRT can be used concurrently 
• NRT can be used by people who are unable to quit smoking 
abruptly with NRT but want to cut smoking frequency as a 
prelude to quitting (the ‘nicotine assisted reduction to stop’ 
[NARS] strategy). 
3.11 The PDG considered evidence from trials where NRT was used by 
people who simply wanted to reduce the amount they smoked but 
had no intention of stopping. Compared with a placebo, the use of 
NRT significantly increased long-term abstinence.  However, these 
trials were conducted in highly controlled circumstances.  
3.12 The NARS strategy (also known as cut down to quit) was discussed 
extensively. The PDG had concerns about recommending it for those 
who want to stop smoking but have found it difficult to quit. Until 
further evidence is available, the PDG recommended that NARS is 
only used in properly designed and conducted research studies (see 
below).  
3.13 Studies are needed to determine how the NARS method could help 
individuals who have unsuccessfully tried to quit smoking in the past 
and those who want to stop, but are adamant that they cannot – or 
will not – attempt to stop immediately. Studies are also needed to 
determine which health professionals can best support the NARS 
strategy – and on how to give advice on this method without deterring 
people from attempting to stop completely.  
3.14 The PDG recognised the potential public health benefits of using the 
NARS strategy as a prelude to quitting. It may help those who have 
repeatedly tried and failed to stop smoking. It may also help those 
who do not want – or feel unable – to quit abruptly. People who only 
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want to reduce their smoking may also benefit from using NRT as 
research studies have found that a proportion of this group will quit 
even though it is not their original intention. However, the PDG 
stressed the need for careful consideration of how it would fit with 
existing treatment services. Care is also needed to ensure that any 
promotion of NARS does not imply that cutting down is an 
appropriate substitute for stopping smoking completely.  
3.15 The PDG stressed that health professionals should know about the 
NARS strategy and its likelihood of success compared with abrupt 
quitting. Such knowledge will ensure they are fully equipped to 
discuss individuals’ doubts and fears about the difficulties of quitting 
and can inform them about the support mechanisms available. These 
include the local NHS Stop Smoking Service, as well as telephone 
quitlines and postal self-help services, all of which are free.    
3.16 The NARS strategy is not seen as an appropriate smoking cessation 
method for pregnant women who smoke. Pregnant women must be 
encouraged to quit as soon as possible. 
3.17 Evidence used in formulating the guidance suggested that the NARS 
strategy was highly cost effective when compared with continued 
smoking, but not compared with abrupt quitting. This suggests that 
NARS would only be cost effective if most people using this method 
would not otherwise have attempted to stop smoking.  
3.18 The PDG recognised that there may be a large group of people who 
only wish to cut down their smoking (and do not expect to quit). 
Others may be interested in using NARS to cut down as a preliminary 
step before quitting. Properly conducted research is needed to 
ascertain the effectiveness and cost effectiveness of these methods 
combined with current quit strategies.  
3.19 Studies of the NARS strategy might consider including: data on short 
and long-term quit rates, biochemically validated, if appropriate; an 
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assessment of behavioural support (content, duration and frequency); 
and the sociodemographic characteristics of participants, including 
their age, gender, socioeconomic status and ethnicity. 
3.20 The PDG believes that the NHS should provide all effective 
pharmacotherapies to people trying to quit smoking (therapies 
currently available are NRT, varenicline and bupropion). They agreed 
that healthcare professionals should consider prescribing a 
combination of NRT patches with other NRT products such as gum, 
inhalers or nasal spray in appropriate clinical circumstances (see 
recommendation 4).  
3.21 The most effective smoking cessation interventions in workplace 
settings are those interventions that have been proven to be effective 
more broadly, such as group therapy, individual counselling and 
pharmacological treatment. 
3.22 Effective smoking cessation aids and services are also highly cost 
effective. 
3.23 There were not sufficient data to estimate the cost effectiveness of 
services for pregnant women who smoke. Specifically, it  was not 
possible to determine which of the following would be more cost 
effective:  
• encourage pregnant women to use NHS stop smoking services 
or other publicly-funded smoking cessation services 
• train midwives to a standard that would allow them to act as 
smoking cessation advisors 
• send members of a dedicated team from the NHS or another 
publicly-funded smoking cessation service to the women’s 
homes.  
3.24 Standard economic analysis is inappropriate for mass media 
campaigns because each campaign is unique and it is not possible to 
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predict what the effect will be. Therefore, the cost effectiveness of a 
campaign cannot be guaranteed in advance. However, the more 
successful campaigns will be extremely cost effective. 
4  Recommendations  
This document is the Institute’s formal guidance on smoking cessation 
services. When writing the recommendations, the PDG (see appendix A) 
considered the evidence of effectiveness (including cost effectiveness), 
fieldwork data and comments from stakeholders. Full details are available on 
the Institute’s website at: www.nice.org.uk/PH010 
The evidence statements that underpin the recommendations are listed in 
appendix C.  
The evidence reviews, supporting evidence statements and economic 
appraisal are available on the Institute’s website at www.nice.org.uk/PH010  
The PDG considers all of the recommended interventions to be cost effective. 
The PDG also considered whether a recommendation should only be 
implemented as part of a research programme, where evidence was lacking. 
For the research recommendations and other gaps in the research, see 
section 6 and appendix D respectively. 
Effective interventions 
The following smoking cessation interventions have been proven to be 
effective. 
Brief interventions 
Brief interventions for smoking cessation involve opportunistic advice, 
discussion, negotiation or encouragement and referral to more intensive 
treatment, where appropriate. They are delivered by a range of primary and 
community care professionals, typically in less than 10 minutes. The package 
provided depends on a number of factors including the individual’s willingness 
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to quit, how acceptable they find the intervention and previous methods they 
have used. It may include one or more of the following: 
• simple opportunistic advice  
• an assessment of the individual’s commitment to quit 
• pharmacotherapy and/or behavioural support  
• self-help material  
• referral to more intensive support such as the NHS Stop Smoking Service. 
(NICE 2006a: www.nice.org.uk/PHI001  
NICE 2006b: 
http://guidance.nice.org.uk/PH5/EffectivenessReview/pdf/English) 
Individual behavioural counselling 
Individual behavioural counselling involves scheduled face-to-face meetings 
between someone who smokes and a counsellor trained in smoking 
cessation. Typically, it involves weekly sessions over a period of at least 4 
weeks after the quit date and is normally combined with pharmacotherapy. 
(Lancaster and Stead 2005a: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001292/frame.
html NICE 2006b: 
http://guidance.nice.org.uk/PH5/EffectivenessReview/pdf/English 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427) 
Group behaviour therapy 
Group behaviour therapy involves scheduled meetings where people who 
smoke receive information, advice and encouragement and some form of 
behavioural intervention (for example, cognitive behavioural therapy). This 
therapy is offered weekly for at least the first 4 weeks of a quit attempt (that is, 
for 4 weeks following the quit date).  It is normally combined with 
pharmacotherapy. 
(NICE 2006b: 
http://guidance.nice.org.uk/PH5/EffectivenessReview/pdf/English 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427 
Stead and Lancaster 2005: 
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www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001007/frame.
html)  
Pharmacotherapies 
Smoking cessation advisers and healthcare professionals may recommend 
and prescribe nicotine replacement therapy (NRT), varenicline or bupropion 
as an aid to help people to quit smoking, along with giving advice, 
encouragement and support, or referral to a smoking cessation service. 
Before prescribing a treatment, they take into account the person’s intention 
and motivation to quit and how likely it is they will follow the course of 
treatment. They should also consider which treatments the individual prefers, 
whether they have attempted to stop before (and how), and if there are 
medical reasons why they should not be prescribed particular 
pharmacotherapies. (NICE 2002: www.nice.org.uk/TA039  
NICE 2006b: 
http://guidance.nice.org.uk/PH5/EffectivenessReview/pdf/English 
NICE 2007: www.nice.org.uk/TA123) 
Self-help materials 
Self-help materials comprise any manual or structured programme, in written 
or electronic format, that can be used by individuals in a quit attempt without 
the help of health professionals, counsellors or group support. Materials can 
be aimed at anyone who smokes, particular populations (for example,  
determined by age or ethnic group) or may be interactively tailored to 
individual need. (Lancaster and Stead 2005b:  
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001118/frame.
html NICE 2006b: 
http://guidance.nice.org.uk/PH5/EffectivenessReview/pdf/English) 
Telephone counselling and quitlines 
Telephone counselling and quitlines provide encouragement and support over 
the telephone to anyone who smokes who wants to quit, or who has recently 
quit. Counsellors can call the client (a proactive service) or the client can call 
the service (a reactive service). (Stead et al 2006: 
  
 23 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002850/frame.
html NICE 2006b: 
http://guidance.nice.org.uk/PH5/EffectivenessReview/pdf/English 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427)  
Mass media 
Mass-media campaigns combine multiple types of media, such as TV, radio 
and national newspaper advertising. They can be used alone to encourage 
and support quit attempts or combined with other activities at local, regional 
and national levels.  
(Gutierrez 2007: http://guidance.nice.org.uk/page.aspx?o=404458) 
Different levels of service 
Department of Health guidance on how to develop effective stop smoking 
services covers three levels: brief interventions, intensive one-to-one support 
and advice, and group interventions. These are frequently referred to as level 
one, level two and level three services, respectively. For a full explanation of 
each level of advice, see the 
Smoking cessation services 
‘Standard for training in smoking cessation 
treatments’ (www.nice.org.uk/page.aspx?o=502591). 
Recommendation 1  
Who is the target population? 
Everyone who smokes or uses any other form of tobacco.  
Who should take action? 
• Primary care trusts (PCTs), strategic health authorities (SHAs). 
• Commissioners of publicly funded smoking cessation services. 
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What action should they take? 
• Determine the characteristics of the local population of people who smoke 
or use other forms of tobacco. Determine the prevalence of all forms of 
tobacco use locally. 
• Ensure NHS Stop Smoking Services target minority ethnic and 
socioeconomically disadvantaged communities in the local population.  
• Ensure NHS Stop Smoking Services provide a good service by maintaining 
adequate staffing levels, including a full-time coordinator (or the 
equivalent). 
• Set realistic performance targets for both the number of people using the 
service and the proportion who successfully quit smoking. These targets 
should reflect the demographics of the local population. Services should: 
− aim to treat at least 5% of the estimated local population of 
people who smoke or use tobacco in any form each year 
− aim for a success rate of at least 35% at 4 weeks, validated 
by carbon monoxide monitoring. This figure should be based 
on all those who start treatment, with success defined as not 
having smoked in the third and fourth week after the quit date. 
Success should be validated by a CO monitor reading of less 
than 10 ppm at the 4-week point. This does not imply that 
treatment should stop at 4 weeks. 
• Audit performance data routinely and independently and make the results 
publicly available. Audits should also be carried out on exceptional results – 
4-week quit rates lower than 35% or above 70% – to determine the reasons 
for unusual performance, and to help identify best practice and ensure it is 
being followed. 
• Establish links between contraceptive services, fertility clinics and  
ante- and postnatal services. These links should ensure health 
professionals use the many opportunities available to them (at various 
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stages of the woman’s life) to offer smoking advice or referral to a specialist 
service, where appropriate.  
(See also NICE public health guidance 1 on smoking cessation in primary 
care and other settings at: www.nice.org.uk/PHI001) 
Recommendation 2 
Who is the target population? 
Everyone who smokes or uses tobacco in any other form. 
Who should take action? 
Managers and providers of NHS Stop Smoking Services.  
What action should they take? 
• Offer behavioural counselling, group therapy, pharmacotherapy or a 
combination of treatments that have been proven to be effective (see the 
list at the start of this section). 
• Ensure clients receive behavioural support from a person who has had 
training and supervision that complies with the ‘Standard for training in 
smoking cessation treatments’ or its updates 
(www.nice.org.uk/page.aspx?o=502591).  
• Provide tailored advice, counselling and support, particularly to clients from 
minority ethnic and disadvantaged groups. Provide services in the 
language chosen by clients, wherever possible.  
• Ensure the local NHS Stop Smoking Service aims to treat minority ethnic 
and disadvantaged groups at least in proportion to their representation in 
the local population of tobacco users.  
(See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001) 
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Recommendation 3 
Who is the target population? 
People who want to stop smoking. 
Who should take action? 
Commissioners and managers of telephone quitline services.  
What action should they take? 
• Ensure publicly sponsored telephone quitlines offer a rapid, positive and 
authoritative response. Where possible, callers whose first language is not 
English should have access to information and support in their chosen 
language.  
• All staff should receive smoking cessation training (at least in brief 
interventions to help people stop smoking). 
• Staff who offer counselling should be trained to at least level two (individual 
behavioural counselling) and preferably, they should hold an appropriate 
counselling qualification. Training should comply with the ‘Standard for 
training in smoking cessation treatments’ or its updates 
(www.nice.org.uk/page.aspx?o=502591).  
Pharmocotherapies and other treatments 
Recommendation 4 
Who is the target population? 
People who want to stop smoking. 
Who should take action? 
Healthcare professionals who advise on, or prescribe, nicotine replacement 
therapy (NRT), varenicline or bupropion.  
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What action should they take? 
• Offer NRT, varenicline or bupropion, as appropriate, to people who are 
planning to stop smoking.  
• Offer advice, encouragement and support, including referral to the NHS 
Stop Smoking Service, to help people in their attempt to quit.  
• NRT, varenicline or bupropion should normally be prescribed as part of an 
abstinent-contingent treatment, in which the smoker makes a commitment 
to stop smoking on or before a particular date (target stop date). The 
prescription of NRT, varenicline or bupropion should be sufficient to last 
only until 2 weeks after the target stop date. Normally, this will be after 2 
weeks of NRT therapy, and 3–4 weeks for varenicline or bupropion, to 
allow for the different methods of administration and mode of action. 
Subsequent prescriptions should be given only to people who have 
demonstrated, on re-assessment, that their quit attempt is continuing.  
• Explain the risks and benefits of using NRT to young people aged from 12 
to 17, pregnant or breastfeeding women, and people who have unstable 
cardiovascular disorders. To maximise the benefits of NRT, people in these 
groups should also be strongly encouraged to use behavioural support in 
their quit attempt.  
• Neither varenicline or bupropion should be offered to young people under 
18 nor to pregnant or breastfeeding women.  
• Varenicline or bupropion may be offered to people with unstable 
cardiovascular disorders, subject to clinical judgement.  
• If a smoker’s attempt to quit is unsuccessful using NRT, varenicline or 
bupropion, do not offer a repeat prescription within 6 months unless special 
circumstances have hampered the person’s initial attempt to stop smoking, 
when it may be reasonable to try again sooner.  
• Do not offer NRT, varenicline or bupropion in any combination. 
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• Consider offering a combination of nicotine patches and another form of 
NRT (such as gum, inhalator, lozenge or nasal spray) to people who show 
a high level of dependence on nicotine or who have found single forms of 
NRT inadequate in the past. 
• Do not favour one medication over another. The clinician and patient 
should choose the one that seems most likely to succeed.  
• When deciding which therapies to use and in which order, discuss the 
options with the client and take into account: 
− whether a first offer of referral to the NHS Stop Smoking 
Service has been made 
− contra-indications and the potential for adverse effects  
− the client’s personal preferences 
− the availability of appropriate counselling or support  
− the likelihood that the client will follow the course of treatment 
− their previous experience of smoking cessation aids.  
This supersedes NICE technology appraisal guidance 39 on NRT and 
bupropion. (See also NICE technology appraisal guidance 123 on varenicline 
at www.nice.org.uk/TA123) 
Recommendation 5 
Who is the target population? 
People who want to stop smoking, but not immediately.  
Who should take action? 
Healthcare professionals who advise on, or prescribe, NRT. 
What action should they take? 
Practitioners should provide NRT and appropriate support to individuals who 
want to follow the nicotine assisted reduction to stop (NARS) strategy only if it 
is part of a properly designed and conducted research study. Participants 
should include those who have repeatedly tried – and failed – to quit and 
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those who are adamant that they do not want to quit abruptly.   
Specific groups 
Recommendation 6 
Who is the target population? 
People receiving care and advice from a health professional in primary care or 
in hospital. 
Who should take action? 
• PCTs and acute trusts. 
• Healthcare professionals. 
What action should they take? 
• Healthcare professionals should be trained to give brief advice on stopping 
tobacco use and should have contact with the local NHS Stop Smoking 
Service to which they can refer people.  
• Healthcare professionals should identify and record the smoking and/or 
tobacco use status of all their patients. Those who use tobacco should be: 
− reminded at every suitable opportunity of the health benefits 
of stopping  
− offered brief advice and, if they want to stop using tobacco, 
referred to the local NHS Stop Smoking Service. If patients do 
not wish to attend the service, they should be offered brief 
advice and support to help them quit, and pharmacotherapy 
as appropriate.  
• Patients referred for elective surgery should be encouraged to stop 
smoking before the operation. Patients who want to stop smoking for good 
should also be referred to the local NHS Stop Smoking Service.  
• Hospital patients who use tobacco in any form should be offered advice 
and, if appropriate, NRT from a trained health professional or smoking 
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cessation adviser while in hospital to help them to quit. They should also be 
offered an appointment with their local NHS Stop Smoking Service. If they 
accept the offer, the appointment should be booked prior to their discharge. 
In exceptional circumstances it might be inappropriate to advise a patient to 
quit; for example, because of their presenting condition or personal 
situation.  
• PCTs should ensure that NHS Stop Smoking Services can provide 
cessation support to hospitals. This should include a fast-track referral 
system after discharge for patients who have tried to quit smoking in 
hospital. PCTs should develop a clear referral plan with links between 
primary and acute trusts. 
(See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001) 
Recommendation 7 
Who is the target population? 
People with cardiovascular or respiratory disease who smoke. 
Who should take action? 
• Healthcare professionals or counsellors who advise on, prescribe or 
dispense pharmacotherapies for stopping smoking.  
• Cardiac rehabilitation teams. 
What action should they take?  
Offer brief advice or, preferably, behavioural support from the local NHS Stop 
Smoking Service and prescriptions of NRT, varenicline or bupropion, 
according to clinical judgement. 
This supersedes NICE technology appraisal guidance 39 on NRT and 
bupropion. (See also NICE technology appraisal guidance 123 on varenicline 
at www.nice.org.uk/TA123 and NICE clinical guideline 12 on chronic 
obstructive pulmonary disease at www.nice.org.uk/CG012) 
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Recommendation 8 
Who is the target population? 
Women who smoke and who are either pregnant or are planning a pregnancy, 
and their partners and family members who smoke. 
Who should take action? 
All those responsible for providing health and support services for pregnant 
women, for those wishing to become pregnant, and for their partners. This 
includes: those working in fertility clinics, midwives, GPs, dentists, hospital 
and community pharmacists, and those working in children’s centres, 
voluntary organisations and occupational health services.  
What action should they take? 
• At the first contact with the woman, discuss her smoking status, provide 
information about the risks of smoking to the unborn child and the hazards 
of exposure to secondhand smoke. Address any concerns she and her 
partner or family may have about stopping smoking.  
• Offer personalised information, advice and support on how to stop 
smoking. Encourage pregnant women to use local NHS Stop Smoking 
Services and the NHS Pregnancy Smoking Helpline by providing details on 
when, where and how to access them. Consider visiting pregnant women 
at home if it is difficult for them to attend specialist services.    
• Monitor smoking status and offer smoking cessation advice, 
encouragement and support throughout the pregnancy and beyond.  
• Discuss the risks and benefits of NRT with pregnant women who smoke, 
particularly those who do not wish to accept the offer of help from the NHS 
Stop Smoking Service. If a woman expresses a clear wish to receive NRT, 
use professional judgement when deciding whether to offer a prescription. 
• Advise pregnant women using nicotine patches to remove them before 
going to bed. 
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This supersedes NICE technology appraisal guidance 39 on NRT and 
bupropion. (See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001) 
Recommendation 9 
Who is the target population? 
Mothers of infants and young children, particularly breastfeeding mothers who 
smoke, and partners and family members who smoke.  
Who should take action? 
GPs, midwives, health visitors, community pharmacists and smoking 
cessation counsellors who advise on, or prescribe, NRT. 
What action should they take?  
• At the first contact, discuss the smoking status of the woman and her 
partner, provide information about the risks of secondhand smoke to young 
children and address any concerns about stopping smoking.  
• Offer information, advice and support on how to quit smoking and 
encourage use of local NHS Stop Smoking Services by providing details on 
when, where and how to access them. 
• Use any opportunity to offer those mothers who are (or who may be) 
eligible for the Healthy Start scheme practical and personalised 
information, advice and support to help them stop smoking.  
• Discuss the risks and benefits of NRT with breastfeeding mothers who 
have tried but have been unable to stop smoking unaided. Use professional 
judgement to decide whether or not to advise use of NRT or to offer an 
NRT prescription. 
• Advise breastfeeding women using nicotine patches to remove them before 
going to bed.  
This supersedes NICE technology appraisal guidance 39 on NRT and 
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bupropion. (See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001) 
Recommendation 10 
Who is the target population? 
Young people aged 12–17 who show a strong commitment to quit smoking. 
Who should take action? 
Healthcare professionals or counsellors who advise on, or prescribe, NRT. 
What action should they take?  
• Offer young people aged 12–17 information, advice and support on how to 
stop smoking. Encourage use of local NHS Stop Smoking Services by 
providing details on when, where and how to access them. 
• Use professional judgement to decide whether or not to offer NRT to young 
people over 12 years who show clear evidence of nicotine dependence. If 
NRT is prescribed, offer it as part of a supervised regime.  
This supersedes NICE technology appraisal guidance 39 on NRT and 
bupropion. (See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001; NICE technology appraisal guidance 123 on 
varenicline at www.nice.org.uk/TA123) 
Education and training  
Recommendation 11 
Who is the target population? 
NHS Stop Smoking Services advisers and coordinators. 
Who should take action? 
Commissioners and managers of NHS Stop Smoking Services. 
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What action should they take? 
• Ensure training and continuing professional development is available for all 
those involved in providing stop smoking advice and support. 
• Ensure training complies with the ‘Standard for training in smoking 
cessation treatments’ or its updates 
(www.nice.org.uk/page.aspx?o=502591).   
Recommendation 12 
Who is the target population? 
Doctors, nurses, midwives, pharmacists, dentists, telephone quitline 
counsellors and others who advise people on how to quit smoking.  
Who should take action? 
Those responsible for the education and training of healthcare workers and 
others who advise people how to quit smoking.  
What action should they take? 
• Train all frontline healthcare staff to offer brief advice on smoking cessation 
in accordance with NICE guidance (‘Brief interventions and referral for 
smoking cessation in primary care and other settings’ 
www.nice.org.uk/PHI001). Also train them to make referrals, where 
necessary and possible, to NHS Stop Smoking Services and other publicly 
funded smoking cessation services.  
• Ensure training on how to support people to quit smoking is part of the core 
curriculum for healthcare undergraduates and postgraduates.  
• Train all NHS Stop Smoking Services practitioners using a programme that 
complies with the ‘Standard for training in smoking cessation treatments’ or 
its updates (www.nice.org.uk/page.aspx?o=502591).  
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• Provide additional, specialised training for those working with specific 
groups, for example, people with mental health problems, those who are 
hospitalised and pregnant women who smoke.   
• Encourage and train healthcare professionals to ask patients or clients 
about all forms of tobacco use and to advise them of the dangers of 
exposure to secondhand smoke. 
Strategies, policies and plans 
Recommendation 13 
Who is the target population? 
Everyone who smokes or uses tobacco in any other form. 
Who should take action? 
PCTs, SHAs, local authorities, local strategic partnerships. 
What action should they take? 
• Set local targets for reducing tobacco use based on the characteristics of 
the local population and the prevalence of smoking and other forms of 
tobacco consumption, such as oral tobacco. Embed these targets in any 
partnership arrangements between local authorities and PCTs (for 
example, local area agreements). 
• Develop a policy to ensure that effective smoking cessation services are 
provided as part of the local tobacco control strategy. 
Recommendation 14 
Who is the target population? 
Everyone who smokes or uses tobacco in any other form. 
Who should take action? 
Organisers and planners of local, regional and national public education and 
communications campaigns. 
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What action should they take? 
• Coordinate communications strategies to support the delivery of smoking 
cessation services, telephone quitlines, school-based interventions, 
forthcoming tobacco control policy changes and any other activities 
designed to help people to stop using tobacco.  
• Develop and deliver communications strategies in partnership with the 
NHS, regional and local government and non-governmental organisations. 
The strategies should:  
− use the best available evidence of effectiveness, such as 
reviews by the Cochrane Collaboration and the Global 
Dialogue for Effective Stop Smoking Campaigns 
(www.stopsmokingcampaigns.org) 
− be developed and evaluated using audience research  
− use ‘why to’ and ‘how to’ quit messages that are non-
judgemental, empathetic and respectful. For example, 
testimonials from people who smoke or used to smoke can 
work well  
− involve community pharmacies in local campaigns and 
maintain links with other professional groups such as dentists, 
fire services and voluntary groups 
− ensure campaigns are sufficiently extensive and sustained to 
have a reasonable chance of success 
− consider targeting and tailoring campaigns towards low 
income and minority ethnic groups to address inequalities. 
Recommendation 15 
Who is the target population? 
People who live or work in prisons, military establishments and care 
institutions, and who smoke or use tobacco in other forms. 
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Who should take action? 
Managers of prisons, military establishments and long-stay health centres, 
such as mental healthcare units. 
What action should they take? 
Develop a policy, using guidance provided by the Department of Health, to 
ensure that effective smoking cessation services are provided and promoted. 
(Go to 
www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Tobacco/ind
ex.htm) 
(See also NICE public health guidance 1 on smoking cessation at: 
www.nice.org.uk/PHI001 and NICE public health guidance 5 on workplace 
smoking cessation at: www.nice.org.uk/PHI005) 
Recommendation 16 
Who is the target population? 
Employees whose workplace is subject to regulations under the 2006 Health 
Act. 
Who should take action? 
Employers.  
What action should they take? 
Negotiate a smokefree workplace policy with employees or their 
representatives. This should: 
• state whether or not smoking breaks may be taken during working hours 
and, if so, where, how often and for how long 
• direct people who wish to stop smoking to services that offer appropriate 
support, for example, the NHS Stop Smoking Services  
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• implement the NICE public health guidance, ‘Workplace interventions to 
promote smoking cessation’ (www.nice.org.uk/PHI005). 
5 Implementation 
NICE guidance can help: 
• NHS organisations meet DH standards for public health as set out in the 
seventh domain of ‘Standards for better health’ (updated in 2006). 
Performance against these standards is assessed by the Healthcare 
Commission, and forms part of the annual health check score awarded to 
local healthcare organisations.  
• NHS organisations and local authorities (including social care and 
children’s services) meet the requirements of the government’s ‘National 
standards, local action, health and social care standards and planning 
framework 2005–2008 and the ‘NHS stop smoking services: service and 
monitoring guidance – October 2007/8’. 
• National and local organisations within the public sector meet government 
indicators and targets to improve health and reduce health inequalities. 
• Local authorities fulfil their remit to promote the economic, social and 
environmental wellbeing of communities. 
• Local NHS organisations, local authorities and other local public sector 
partners benefit from any identified cost savings, disinvestment 
opportunities or opportunities for re-directing resources. 
• Provide a focus for children’s trusts, health and wellbeing partnerships and 
other multi-sector partnerships working on health within a local strategic 
partnership.  
NICE has developed tools to help organisations implement this guidance. For 
details see our website at www.nice.org.uk/PH010 
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6 Recommendations for research 
The Programme Development Group recommends that the following research 
questions should be addressed to fill the most important gaps in the evidence. 
Recommendation 1 
Who should take action? 
Research commissioners and funders. 
What action should they take? 
Commission research on the most effective and cost effective ways to prevent 
relapse among those who have been able to quit smoking.  
Recommendation 2 
Who should take action? 
Research commissioners and funders. 
What action should they take? 
Commission research to determine the long-term outcomes of NHS Stop 
Smoking Services, particularly among minority ethnic and disadvantaged 
communities. The research should analyse access to and uptake of the 
service, compliance with treatment and outcomes, according to people’s 
socioeconomic status, age, gender, disability and ethnicity. It should also 
analyse the individual’s experience of, and satisfaction with, the service. 
Recommendation 3 
Who should take action? 
Research commissioners and funders. 
What action should they take? 
Commission research to determine whether the nicotine assisted reduction to 
stop (NARS) strategy helps individuals to stop smoking completely within a 
12-month period – even though initially they were only willing to cut down.  
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Recommendation 4 
Who should take action? 
Research commissioners and funders. 
What action should they take? 
Commission research to determine the effectiveness of smoking cessation 
interventions delivered through new media such as podcasts, email and text 
messaging.  
Recommendation 5 
Who should take action? 
Research commissioners and funders. 
What action should they take? 
Commission research to determine the comparative effectiveness and cost 
effectiveness of both types of telephone quitline – proactive (contact made by 
counsellors) and reactive (contact made by people who smoke).  
Recommendation 6 
Who should take action? 
Research commissioners and funders. 
What action should they take? 
Commission high quality and, where appropriate, comparative studies to 
evaluate the long-term effectiveness of cytisine for smoking cessation.   
Recommendation 7 
Who should take action? 
Research commissioners and funders. 
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What action should they take? 
Commission high quality and, where appropriate, comparative studies to 
determine the short- and long-term effectiveness of Allen Carr’s Easyway 
method of stopping smoking. Studies should also analyse the individual’s 
experience of, and satisfaction with, the service. 
7 Updating the recommendations  
NICE public health guidance is updated as needed so that recommendations 
take into account important new information. We check for new evidence 2 
and 4 years after publication, to decide whether all or part of the guidance 
should be updated. If important new evidence is published at other times, we 
may decide to update some recommendations at that time. 
8 Related NICE guidance 
MI: secondary prevention in primary and secondary care for patients following 
a myocardial infarction. NICE clinical guideline 48 (2007). Available from: 
www.nice.org.uk/CG048 
Varenicline for smoking cessation. NICE technology appraisal guidance 123 
(2007). Available from: www.nice.org.uk/TA123 
Workplace health promotion: how to help employees to stop smoking. NICE 
public health intervention guidance 5 (2007). Available from: 
www.nice.org.uk/PHI005 
Brief interventions and referral for smoking cessation in primary care and 
other settings. NICE public health intervention guidance 1 (2006). Available 
from: www.nice.org.uk/PHI001  
Chronic obstructive pulmonary disease: management of chronic obstructive 
pulmonary disease in adults in primary and secondary care. NICE clinical 
guideline 12 (2004).Available from: www.nice.org.uk/CG012 
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Guidance on the use of nicotine replacement therapy (NRT) and bupropion for 
smoking cessation. NICE technology appraisal 39 (2002). Available from: 
www.nice.org.uk/TA039  
Under development 
Antenatal care: routine care for the healthy pregnant woman. NICE clinical 
guideline (due March 2008). 
Preventing the uptake of smoking among children and young people, 
including point of sale measures. NICE public health guidance (due July 
2008). 
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Appendix A: membership of the Programme 
Development Group, the NICE Project Team and 
external contractors 
The Programme Development Group 
PDG membership is multidisciplinary. It comprises researchers, practitioners, 
stakeholder representatives and members of the public as follows:  
Deborah Arnott Director, Action on Smoking and Health, London 
Dr Paul Aveyard Senior Scientist, National Institute of Health Research, 
Department of Primary Care and General Practice, University of Birmingham 
Professor John Britton Head, Division of Epidemiology and Public Health, 
University of Nottingham 
Ron Gould Member, Liverpool City Council; Community Pharmacist 
Professor Hilary Graham Professor of Health Sciences, University of York; 
Director, Department of Health Public Health Research Consortium 
Ian Gray Policy Officer, Chartered Institute of Environmental Health 
Professor Gerard Hastings Director, Institute for Social Marketing and 
Centre for Tobacco Control Research, University of Stirling & Open University 
Andrew Hayes Tobacco Policy Manager, Regional Public Health Group for 
London 
Paul Hooper Tobacco Policy Manager, Regional Public Health Group, West 
Midlands 
(CHAIR) Sir Alexander Macara Public Health Physician; President, National 
Heart Forum Board of Trustees 
Carmel O’Gorman Midwifery Lead, Smoking Cessation in Pregnancy, 
Goodhope Hospital, West Midlands 
  
 47 
Dr Kiran Patel Consultant Cardiologist, Sandwell Hospital, Sandwell and 
West Birmingham Hospitals NHS Trust; Honorary Senior Lecturer, University 
of Birmingham, Department of Cardiovascular Medicine; Chair, South Asian 
Health Foundation 
Dr Mike Ward Consultant Physician, Sherwood Forest Hospitals 
Professor Robert West Director, Tobacco Studies, UK Health Behaviour 
Research Centre, University College, London 
Expert cooptees to the PDG: 
Professor Peter Hajek Director, Tobacco Dependence Research Centre, 
Queen Mary University of London 
Community members 
Ruth Bosworth Director of Services, QUIT 
David Geldard President of Heart Care Partnership (UK); Council Member, 
British Cardiovascular Society 
Christine Owens Head of Tobacco Control, Roy Castle Lung Cancer 
Foundation 
Pamela Rees Inequalities and Smoking Manager, Directorate of Public 
Health, Leicester City Primary Care Trust 
NICE Project Team 
Mike Kelly 
CPHE Director 
Tricia Younger 
Associate Director  
Patti White 
Lead Analyst  
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Lesley Owen 
Analyst 
Hugo Crombie 
Analyst 
Alastair Fischer 
Health Economics Adviser 
External contractors 
External reviewers: effectiveness reviews 
Review 1: ‘Rapid review of non NHS treatments of smoking cessation’ carried 
by the University of Auckland and Queen Mary, University of London. The 
principal authors were: Professor Peter Hajek and Dr Hayden McRobbie 
(University of Auckland). 
Review 2: ‘The effectiveness of National Health Service intensive treatments 
for smoking cessation in England’ carried out by the British Columbia Centre 
of Excellence for Women’s Health. The principal authors were: Dr Linda 
Bauld, Dr Kirsten Bell, Karen DeVries, Dr Lorraine Greaves, Natasha 
Jatageonkar and Lucy McCullough. 
Review 3: ‘Workplace policies for smoking cessation’ carried out from May–
September 2006 and updated in January 2007 by the British Columbia Centre 
of Excellence for Women’s Health. The principal authors were:  
Dr Kirsten Bell, Karen DeVries, Dr Lorraine Greaves, Natasha Jatageonkar 
and Lucy McCullough.  
Review 4: ‘A review of the effectiveness of mass media interventions which 
both encourage quit attempts and reinforce current and recent attempts to quit 
smoking’ carried out by the Cancer Care Research Centre and Centre for 
Social Marketing, the University of Stirling and the Alliance for Self Care 
Research, University of Abertay. The principal authors were: Fiona Harris, 
Gerard Hastings, Ruth Jepson, Nora Kearney, Steve MacGillivray and Neneh 
Rowa-Dewar.  
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Review 5: ‘The impact of quitlines on smoking cessation’ carried out by the 
British Columbia Centre of Excellence for Women’s Health. The principal 
authors were: Dr Kirsten Bell, Dr Lorraine Greaves and Lindsay Richardson. 
External reviewers: expert report 
Expert paper: ‘Mass media interventions to stimulate and promote smoking 
cessation’ prepared by Karen K Gutierrez, Director, Global Dialogue for 
Effective Stop Smoking Campaigns. 
External reviewers: economic reviews and analysis for the update of 
NICE technology appraisal guidance 39  
‘Cut down to quit with nicotine replacement therapies (NRT) in smoking 
cessation: systematic review of effectiveness and economic analysis’ carried 
out by the West Midlands Health Technology Assessment Collaboration, 
Department of Public Health and Epidemiology, University of Birmingham. 
The principal authors were: Paul Aveyard, Pelham Barton, Martin Connock, 
Anne Fry-Smith, David Moore and Dechao Wang. 
‘Clinical and cost-effectiveness of nicotine replacement therapy for new 
licensed indications and combination therapy: a summary of best evidence’ 
carried out by the Aggressive Research Intelligence Facility, West Midlands 
Health Technology Assessment Collaboration. The principal authors were: 
Anne Fry-Smith, Chris Hyde, David Moore, Jon Roberts and Josie 
Sandercock. 
External reviewers: economic evaluations 
The economic evaluation ‘A rapid review of the cost effectiveness of non-
National Health Service treatments for smoking cessation in England’ was 
carried out by York Health Economics Consortium. The principal authors 
were: Sarah Flack, Matthew Taylor and Paul Trueman. 
The economic evaluation ‘A rapid review of the cost effectiveness of National 
Health Service treatments for smoking cessation in England’ was carried out 
by York Health Economics Consortium. The principal authors were: Sarah 
Flack, Matthew Taylor and Paul Trueman. 
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The economic evaluation ‘A rapid review of the cost effectiveness of 
workplace policies for smoking cessation in England’ was carried out by York 
Health Economics Consortium. The principal authors were: Sarah Flack, 
Matthew Taylor and Paul Trueman. 
The economic evaluation ‘A rapid review of the cost effectiveness of mass 
media interventions for smoking cessation in England’ was carried out by York 
Health Economics Consortium. The principal authors were: Sarah Flack, 
Matthew Taylor and Paul Trueman. 
External reviewers: economic analyses 
The economic analysis ‘Cost effectiveness of interventions for smoking 
cessation’ was carried out by the York Health Economic Consortium. The 
authors were: Sarah Flack, Matthew Taylor and Paul Trueman.  
The economic analysis ‘Cost effectiveness of interventions for smoking 
cessation: mass media’ was carried out by the York Health Economic 
Consortium. The authors were: Sarah Flack, Matthew Taylor and Paul 
Trueman.  
The economic analysis ‘Cost impact analysis of interventions for smoking 
cessation aimed at pregnant women’ was carried out by the York Health 
Economic Consortium. The authors were: Sarah Flack, Matthew Taylor and 
Paul Trueman.  
Fieldwork 
The fieldwork was carried out by Nigel Jackson of Dr Foster Intelligence. 
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Appendix B: summary of the methods used to develop 
this guidance 
Introduction 
The reports of the reviews, expert reports and economic analyses include full 
details of the methods used to select the evidence (including search 
strategies), assess its quality and summarise it. The minutes of the PDG 
meetings provide further detail about the Group’s interpretation of the 
evidence and development of the recommendations. 
All supporting documents are listed in appendix E and are available from the 
NICE website at: www.nice.org.uk/PH010 
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The guidance development process 
The stages of the guidance development process are outlined in the box 
below: 
1. Draft scope  
2. Stakeholder meeting  
3. Stakeholder comments  
4. Final scope and responses published on website 
5. Reviews and cost-effectiveness modelling 
6. Synopsis report of the evidence (executive summaries and evidence tables) 
circulated to stakeholders for comment 
7. Comments and additional material submitted by stakeholders 
8. Review of additional material submitted by stakeholders (screened against 
inclusion criteria used in reviews)  
9. Synopsis, full reviews, supplementary reviews and economic modelling 
submitted to the PDG 
10.The PDG produces draft recommendations 
11. Draft recommendations published on website for comment by 
stakeholders and for field testing 
12. The PDG amends recommendations 
13. Responses to comments published on website 
14. Final guidance published on website 
Key questions 
The key questions were established as part of the scope. They formed the 
starting point for the reviews of evidence and facilitated the development of 
recommendations by the PDG. The overarching question was: ‘What is the 
optimal provision of smoking cessation services, including the provision of 
nicotine replacement therapy (NRT), for primary care, pharmacies, local 
authorities and workplaces, with particular reference to manual working 
groups, pregnant women who smoke and hard to reach communities?’ The 
subsidiary questions were: 
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1. What is the aim or objective? 
2. What is the content and how does it influence effectiveness? 
3. How does the way that the intervention is carried out influence 
effectiveness? 
4. Does effectiveness depend on the job title/position of the person 
delivering the intervention? What are the significant features of an 
effective leader? 
5. Does the site/setting influence effectiveness? 
6. Does the intensity (or length or frequency) influence effectiveness or 
duration of effect? 
7.  How does effectiveness vary according to factors such as the age, sex, 
class or ethnicity of the target audience? 
8.  How much does the intervention cost (in terms of money, people, 
time)?  
9.  What evidence is there on cost effectiveness? Does the intervention 
offer value for money? 
10  What are the facilitators and barriers to implementation? 
These questions were refined further in relation to the topic of each review 
(see reviews for further details). 
Reviewing the evidence of effectiveness 
Five reviews of effectiveness were conducted. 
Identifying the evidence  
The following databases were searched for meta-analyses, systematic 
reviews of randomised controlled trials (RCTs), individual RCTs, systematic 
reviews of non-RCTs, case-control studies, cohort studies, interrupted time 
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series studies, correlational studies, controlled before-and-after studies, non-
analytic studies (for example case reports, case studies) and expert opinion 
(1900–2007):  
• AMED 
• ASSIA 
• British Nursing Index  
• CINAHL 
• Cochrane Database of Systematic Reviews  
• Cochrane Controlled Trials Register (CENTRAL)  
• Controlled Clinical Trials  
• Database of Abstracts of Reviews of Effects 
• DARE  
• DH-Data 
• EMBASE  
• Google Scholar 
• Health Technology Assessment Database  
• HSTAT 
• King’s Fund  
• MEDLINE (Ovid) 
• National Guideline Clearinghouse 
• National Research Register (including CRD ongoing reviews database 
and unpublished reports)  
• NICE web pages (published appraisals) 
• PsycINFO  
• SIGN Guidelines 
• Sociological Abstracts  
• TRIP. 
In addition, for the NHS Stop Smoking Services review, telephone interviews 
were carried out with 12 people working in tobacco cessation. 
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These questions were refined further in relation to the topic of each review 
(see reviews for further details).  
Expert report 
The expert report on mass media interventions (see appendix A for details) 
identified both unpublished and published data produced between 1996 and 
2006. 
Further details of the databases, search terms and strategies are included in 
the review reports.  
Selection criteria 
Inclusion and exclusion criteria for each review (see appendix A for details) 
varied and details can be found at www.nice.org.uk/PH010 However, in 
general:  
• Review 1 included systematic reviews and meta-analyses that focused on 
the most widely advertised, commercially available smoking cessation 
treatments in the UK. This included pharmacological and behavioural 
treatments where there was published research available on their effects. 
• Review 2 included reviews, RCTs and non-randomised studies that 
evaluated the effectiveness of intensive treatments for smoking within the 
NHS, in particular, those offered by the NHS Stop Smoking Services.  
• Review 3 included reviews and other studies of selective or indicated 
interventions  that evaluated the effectiveness of workplace policies in 
England to support smoking cessation. 
• Review 4 included reviews and other studies on mass media and 
community interventions that both encourage quit attempts and reinforce 
current and recent attempts to quit smoking among all population groups.   
• Review 5 included reviews and other studies of telephone interventions for 
smoking cessation where telephone support was a key intervention 
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component, or an adjunct to brief advice, and where it could be evaluated 
independently of the other intervention components. 
• The expert paper on mass media interventions for smoking cessation 
included data (both published and unpublished) produced over the last 10 
years (1996–2006). 
Quality appraisal 
Included papers were assessed for methodological rigour and quality using 
the NICE methodology checklist, as set out in the NICE technical manual 
‘Methods for development of NICE public health guidance’ (see appendix E). 
Each study was described by study type and graded (++, +, -) to reflect the 
risk of potential bias arising from its design and execution: 
Study type 
• Meta-analyses, systematic reviews of RCTs or RCTs (including cluster 
RCTs). 
• Systematic reviews of, or individual, non-RCTs, case-control studies, 
cohort studies, controlled before-and-after studies, interrupted time series 
studies, correlation studies.  
• Non-analytical studies (for example, case reports, case series). 
• Expert opinion, formal consensus. 
Study quality 
++  All or most of the criteria have been fulfilled. Where they have not been 
fulfilled the conclusions are thought very unlikely to alter. 
+  Some criteria have been fulfilled. Those criteria that have not been 
fulfilled or not adequately described are thought unlikely to alter the 
conclusions. 
-  Few or no criteria fulfilled. The conclusions of the study are thought 
likely or very likely to alter. 
The studies were also assessed for their applicability to the UK.  
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Summarising the evidence and making evidence statements 
The review data was summarised in evidence tables (see full reviews and the 
synopsis).  
The findings from the reviews, interviews and expert report were synthesised 
and used as the basis for a number of evidence statements relating to each 
key question. The evidence statements reflect the strength (quantity, type and 
quality) of evidence and its applicability to the populations and settings in the 
scope. 
Further details of the databases, search terms and strategies are included in 
the review reports. 
Economic appraisal 
The economic appraisal consisted of four economic evaluations and three 
economic analyses (See appendix A for details). 
Review of economic evaluations 
Three databases were searched for each cost-effectiveness review: NHS 
Economic Evaluation Database, Centre for Reviews and Dissemination (CRD) 
and the internal database results from the original effectiveness review. 
The criteria for inclusion of papers were: 
• studies used a defined intervention to assist smoking cessation  
• the study population was smoking at the start of the study (although if 
drawn from a general population, it is accepted that some people may not 
smoke) 
• studies reported both the costs and effectiveness of an intervention 
(although costs and effectiveness did not have to be combined into a 
single cost-effectiveness ratio). 
Ten papers were identified for the mass media economic review, no papers 
were identified for the economic review of non-NHS interventions, 18 papers 
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were identified for NHS interventions and 10 papers were identified for 
workplace interventions. 
Cost-effectiveness analysis 
A cohort simulation model was designed to estimate the costs and quality-
adjusted life years (QALYs) associated with smoking cessation. The model 
was designed to compare different smoking cessation interventions to 
determine their incremental cost-effectiveness.  
To furnish the model with relevant data, the following databases were 
searched: MEDLINE and MEDLINE In-Process, NHS EED, HEED, CINAHL, 
HMIC, CRD (internal database) and PubMed. The World Wide Web and 
references listed in identified articles were also searched for relevant studies.  
Data were gathered on the following: 
• mortality, by age, gender and smoking status 
• prevalence of each comorbidity by age, gender and smoking status 
• utilities for each comorbidity 
• costs for each comorbidity 
• the annual cessation and cost of each intervention modelled. 
The results are reported in: ‘Cost effectiveness of interventions for smoking 
cessation’ (Flack et al. 2007a) and ‘Cost impact analysis of workplace-based 
interventions for smoking cessation’ (Flack et al. 2007b). These reports are 
available on the NICE website at www.nice.org.uk/PH010 
Review of NICE technology appraisal 39: reviewing the 
evidence of effectiveness 
Two effectiveness reviews were conducted to inform the update of NICE 
technology appraisal 39. 
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Identifying the evidence  
‘Cut down to quit with nicotine replacement therapies (NRT) in smoking 
cessation: systematic review of effectiveness and economic analysis’.  
Searches were carried out for systematic reviews and primary studies from 
1992–2006 on the following databases: Cochrane reviews, Cochrane 
Collaboration (via Cochrane Library), Database of Abstracts of Reviews of 
Effectiveness (DARE), Cochrane Central Register of Controlled Trials 
(CENTRAL), Health Technology Assessment (HTA) database and ARIF 
Database, NHS CRD, Bandolier, TRIP, MEDLINE, EMBASE, CINAHL and 
PsycINFO. 
Information was also gathered from the Science Citation Index (Web of 
Science), National Research Register and citations of relevant studies and 
reviews. In addition, further information was sought from regional experts, 
especially Pharmacy Prescribing Unit, Keele University (&MTRAC) and the 
West Midlands Drug Information Service (url: www.ukmicentral.nhs.uk) and 
from licensing authority and industry documents. 
‘Clinical and cost-effectiveness of nicotine replacement therapy for new 
licensed indications and combination therapy: a summary of best 
evidence’.  
Specific searches related to the aims of each report were carried out in the 
following databases: The Cochrane Library, MEDLINE (1966–2006) and 
EMBASE (1980–2006). Generic searches were also conducted to gather cost-
effectiveness information in: OHE HEED (August 2006) and MEDLINE. 
Searches for ongoing studies were conducted in the National Research 
Register.  
Further details of the databases, search terms and strategies are included in 
the review reports.  
Selection criteria 
Inclusion and exclusion criteria for the Cut down to quit (CDTQ) reviews were: 
  
 60 
• at least one electronic database (for example, MEDLINE) was scrutinised 
using a stated search strategy 
• RCT studies of CDTQ were reviewed 
• quit rates were quantitatively reviewed and/or meta-analysed. 
Inclusion and inclusion criteria for primary studies of CDTQ were: 
• RCTs were undertaken of people who were currently unable or unwilling to 
quit smoking abruptly 
• interventions included the use of NRT gum or NRT inhalator alone, or as 
part of combination therapy (for example, motivational support) 
• the comparator was: placebo or no treatment, non-NRT drugs for smoking 
cessation, psychological interventions (for example, motivational support) 
for quitting. Where an adjunct therapy was used in the intervention it had 
to be used with the comparator 
• quit rates had to be provided. 
Quality appraisal 
Included papers were assessed for methodological rigour and quality using 
the NICE methodology checklist, as set out in the NICE technical manual 
‘Methods for development of NICE public health guidance’ (see appendix E). 
Each study was described by study type and graded (++, +, -) to reflect the 
risk of potential bias arising from its design and execution: 
Study type 
• Meta-analyses, systematic reviews of RCTs or RCTs (including cluster 
RCTs). 
• Systematic reviews of, or individual, non-randomised controlled trials, case-
control studies, cohort studies, controlled before-and-after studies, 
interrupted time series studies, correlation studies.  
• Non-analytical studies (for example, case reports, case series). 
• Expert opinion, formal consensus. 
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Study quality 
++  All or most of the criteria have been fulfilled. Where they have not been 
fulfilled the conclusions are thought very unlikely to alter. 
+  Some criteria have been fulfilled. Those criteria that have not been 
fulfilled or not adequately described are thought unlikely to alter the 
conclusions. 
-  Few or no criteria fulfilled. The conclusions of the study are thought 
likely or very likely to alter. 
The studies were also assessed for their applicability to the UK.  
Review of NICE technology appraisal 39: economic appraisal 
The economic appraisal consisted of two effectiveness reviews. 
Review of economic evaluations 
‘Cut down to quit with nicotine replacement therapies (NRT) in smoking 
cessation: systematic review of effectiveness and economic analysis’. The 
following databases were searched: Cochrane Library (Wiley) 2006 Issue 2, 
MEDLINE (Ovid) 1992–July 2006, MEDLINE In-Process (Ovid) 12 July 2006, 
EMBASE (Ovid) 1992–week 27 2006, CINAHL (Ovid) 1992–July 2006, 
PsycINFO (Ovid) 1992–July 2006, Science Citation Index (Web of Science) 
1992–July 2006. 
In addition, other searches included the research registries of ongoing trials: 
National Research Register 2006 Issue 2, Current Controlled Trials 
metaRegister and ClinicalTrials.gov, and citations of relevant studies and 
reviews. Further information was also sought from experts and from licensing 
authority and industry documents. 
Relevant systematic reviews, randomised controlled trials and existing 
economic analyses of CDTQ were identified.  
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RCTs were included if: 
• the population consisted of people who were unable or unwilling to attempt 
to quit smoking in the short term 
• the interventions encompassed a cut-down smoking programme supported 
by NRT 
• the comparator was a cut-down programme with placebo or other support.  
Systematic reviews were included if: 
• at least one electronic database had been searched and RCTs 
documenting quit rates in NRT smoking reduction programmes were 
reviewed. 
Economic studies were included if they encompassed cost effectiveness or 
cost-utility analysis of CDTQ programme(s). 
‘Clinical and cost-effectiveness of nicotine replacement therapy for new 
licensed indications and combination therapy: a summary of best 
evidence’.  
The following databases were searched: MEDLINE, EMBASE, the Cochrane 
library and OHE HEED. Studies were included if they covered:  
• NRT 
• the relevant population/combination as a systematic review  
• the relevant population/combination as an RCT (if a systematic review was 
identified only more recent RCTs were sought). 
Cost effectiveness analysis 
‘Cut down to quit with nicotine replacement therapies (NRT) in smoking 
cessation: systematic review of effectiveness and economic analysis’.  
No existing economic analyses of CDTQ were identified. A ‘de novo’ decision 
analytic model was constructed to estimate the cost-effectiveness of making 
CDTQ with NRT available for people who were unwilling or unable to attempt 
an abrupt quit. The outcome measure was expected quality-adjusted life years 
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(QALYS). The model also took account of the possibility that some people 
willing to attempt abrupt quitting might instead switch to CDTQ. People 
moving from an abrupt quit attempt to CDTQ were assumed to either 
experience a ‘CDTQ success rate’ or to retain the abstinence success rate of 
abrupt quitters. 
‘Clinical and cost-effectiveness of nicotine replacement therapy for new 
licensed indications and combination therapy: a summary of best 
evidence’.  
There were no economic analyses specifically addressing the cost 
effectiveness of NRT for adolescents, pregnant women, breastfeeding 
women, combination therapy NRT + NRT, combination therapy NRT + 
bupropion or cardiovascular patients.  
It was not possible to undertake any modelling with the resources available. 
Searches for existing models did not identify any models for adolescents, 
pregnancy, breastfeeding, cardiovascular disease or combination treatment. 
Fieldwork 
Fieldwork was carried out to evaluate the relevance and usefulness of NICE 
guidance for practitioners and the feasibility of implementation. It was 
conducted with practitioners and commissioners who are involved in smoking 
cessation services. They included those working in general practice, maternity 
services, secondary care, community pharmacies, dentistry, strategic health 
authorities and primary care teams, NHS Stop Smoking Services and regional 
networks in the NHS and appropriate charities. 
The fieldwork comprised:  
• Group discussions carried out in Greater Manchester, Kirklees, 
Merseyside, Leicester, London and the South East, Birmingham and West 
Midlands with: 
− smoking cessation teams 
− GPs 
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− practice nurses 
− community pharmacists 
− dentists 
− midwives 
− hospital staff  
− SHA directors of public health. 
• In-depth interviews were conducted individually, in pairs and in trios in 
Greater Manchester, Kirklees, Merseyside, Leicester, London and the 
South East, Birmingham and the West Midlands and by telephone.  
• The studies were commissioned to ensure there was ample geographical 
coverage. The main issues arising from the five group discussions and 23 
in-depth interviews with individual professionals either singly, in pairs or in 
trios, are set out in appendix C under ‘Fieldwork findings’. The full fieldwork 
report is available on the NICE website:www.nice.org.uk/PH010 
How the PDG formulated the recommendations 
At its meetings held between May 2006 and September 2007, the PDG 
considered the evidence of effectiveness, expert reports and cost 
effectiveness to determine: 
• whether there was sufficient evidence (in terms of quantity, quality and 
applicability) to form a judgement 
• whether, on balance, the evidence demonstrates that the intervention is 
effective or ineffective, or whether it is equivocal 
• where there is an effect, the typical size of effect. 
The PDG developed draft recommendations through informal consensus, 
based on the following criteria: 
• strength (quality and quantity) of evidence of effectiveness and its 
applicability to the populations/settings referred to in the scope 
• effect size and potential impact on population health and/or reducing 
inequalities in health 
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• cost effectiveness (for the NHS and other public sector organisations) 
• balance of risks and benefits 
• ease of implementation and the anticipated extent of change in practice 
that would be required. 
The PDG also considered whether a recommendation should only be 
implemented as part of a research programme, where evidence was lacking.  
Where possible, recommendations were linked to an evidence statement(s) 
(see appendix C for details). Where a recommendation was inferred from the 
evidence, this was indicated by the reference ‘IDE’ (inference derived from the 
evidence). 
The draft guidance, including the recommendations, was released for 
consultation in May 2007. At its meetings in June and September 2007, the 
PDG considered comments from stakeholders and the results from fieldwork 
The guidance was signed off by the NICE Guidance Executive in December 
2007. 
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Appendix C: the evidence  
This appendix sets out the evidence statements taken from five reviews, and 
the expert report and links them to the relevant recommendations (see 
appendix B for the key to study types and quality assessments). The evidence 
statements are presented here without references – these can be found in the 
full review (see appendix E for details). It also sets out a brief summary of 
findings from the economic appraisal and the fieldwork.  
The five reviews of effectiveness are:  
Review 1: ‘Rapid review of non-NHS treatments of smoking cessation’ 
Review 2: ‘The effectiveness of National Health Service intensive treatments 
for smoking cessation in England’ 
Review 3: ‘Workplace policies for smoking cessation’ 
Review 4: ‘A review of the effectiveness of mass media interventions which 
both encourage quit attempts and reinforce current and recent attempts to quit 
smoking’ 
Review 5: ‘The impact of quitlines on smoking cessation’. 
Evidence statement 1.2 indicates that the linked statement is numbered 2 in 
the review ‘Rapid review of non NHS treatments of smoking cessation’. 
Evidence statement 5.3 indicates that the linked statement is numbered 3 in 
the review ‘The impact of quitlines on smoking cessation’. 
The reviews, expert report, economic appraisal and fieldwork report are 
available on the NICE website (www.nice.org.uk/PH010). Where a 
recommendation is not directly taken from the evidence statements, but is 
inferred from the evidence, this is indicated by IDE (inference derived from the 
evidence). 
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Where the PDG has considered other evidence, it is linked to the appropriate 
recommendation below. It is also listed in the additional evidence section of 
this appendix. 
Recommendation 1: evidence statements 2.1, 2.2, 2.3, 2.5, 2.17, 2.22, 2.25, 
2.26, 2.27; IDE 
Recommendation 2: evidence statements 2.1, 2.2, 2.3, 2.20, 2.25, 2.26, 
2.27, 2.28, 2.29, 2.30; IDE 
Recommendation 3: evidence statements 5.1, 5.3, 5.17; IDE 
Recommendation 4: University of Birmingham 2006; NICE 2002; NICE 2007; 
IDE 
Recommendation 5: Wang et al. 2006; IDE 
Recommendation 6: evidence statements 2.1, 2.2, 2.3, 2.5, 2.9; IDE 
Recommendation 7: evidence statements 2.1, 2.2, 2.3, 2.4; University of 
Birmingham 2006; NICE 2002; NICE 2007; IDE 
Recommendation 8: evidence statements, 2.1, 2.2, 2.3, 2.4, 2.22, 2.23; 
University of Birmingham 2006; IDE 
Recommendation 9: evidence statements 2.1, 2.2, 2.3, 2.4; University of 
Birmingham 2006; IDE 
Recommendation 10: evidence statements 2.1, 2.2, 2.3, 2.4; University of 
Birmingham 2006; NICE 2002; NICE 2007; IDE 
Recommendation 11: IDE 
Recommendation 12: IDE 
Recommendation 13: IDE 
Recommendation 14: evidence statements 2.4, 4.8, 4.24, 4.26, 4.27; 
Gutierrez 2007; IDE 
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Recommendation 15: evidence statements 2.31, 2.32, 2.34; IDE 
Recommendation 16: evidence statements 3.1, 3.2, 3.3, 3.10, 3.20  
Research recommendation 1: IDE 
Research recommendation 2: evidence statements 2.2, 2.8, 2.17, 2.18, 
2.19, 2.20, 2.21, 2.25, 2.33; IDE 
Research recommendation 3: Wang et al. (2006) 
Research recommendation 4: evidence statements 4.3, 4.10, 4.11, 4.21, 
4.28; Gutierrez (2007) 
Research recommendation 5: evidence statements 5.4, 5.13   
Research recommendation 6: evidence statement 1.7 
Research recommendation 7: evidence statements 1.2, 3.1 
Evidence statements 
Evidence statement 1.2 
There are no controlled data available on the efficacy of Allen Carr’s Easyway 
Programme. Two of four cohort follow-up studies report high smoking 
cessation rates but this evidence is weak and further research is needed to 
determine their effectiveness. 
Evidence statement 1.7 
Level 1 (+) evidence from one randomised controlled trial shows that cytisine 
improves 6-month abstinence rates. 
Evidence statement 2.1 
Six 3 (-) reports and one 2 (++) study provide evidence that intensive 
interventions for smoking cessation through the NHS Stop Smoking Services 
appear to be effective in the short term; on average, over half of the clients 
setting quit dates through the services self-report as quit at 4 weeks. 
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However, these statistics should be treated with some caution as it appears 
that PCTs are using different baselines to measure success. As all seven 
studies took place within the English smoking cessation services, they are 
directly applicable to the target population. 
Evidence statement 2.2 
One 3 (-) report, one 2 (-) study, two 2 (+) studies and one 2 (++) study 
provide evidence that intensive interventions for smoking cessation through 
the NHS Stop Smoking Services appear to be reasonably effective in the long 
term. On average, between 13% and 23% of the clients who self-report as 
successful quitters at 4 weeks through the services self-report as abstinent at 
52 weeks – a long-term success rate that is broadly consistent with 
international findings. As all studies took place within the English smoking 
cessation services, they are directly applicable to the target population. 
Evidence statement 2.3 
Evidence from two 3 (-) bulletins indicates that intermediate interventions 
delivered by community advisers achieve self-reported cessation rates of 
between 34% and 45% at 4 weeks. These results do not necessarily reflect 
the outcomes currently being achieved by these interventions, given the 
substantial development of the services since 2001. As these studies took 
place within English smoking cessation services, they are directly relevant to 
the target population. 
Evidence statement 2.4 
Evidence from a 1 (++) systematic review indicates that pharmacy-delivered 
interventions may have a positive effect on smoking cessation rates. This 
finding is confirmed in a recent 2 (++) study which reports that pharmacy 
delivered interventions in Glasgow produce 4-week CO-validated quit rates of 
approximately 20%. The study also indicates that pharmacy-delivered 
interventions have the potential to reach and treat large numbers of smokers – 
especially those from disadvantaged areas. As these studies took place within 
UK smoking cessation services, they are directly relevant to the target 
population. 
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Evidence statement 2.5 
Two studies provide a body of 2 (++) evidence that group interventions may 
produce higher CO-validated quit rates at 4 weeks than one-to-one 
interventions. However, one-to-one interventions are also effective and many 
clients express a clear preference for one-to-one treatment. Moreover, in 
some contexts (particularly rural areas), group treatment is simply unfeasible. 
Therefore, one-to-one interventions are a crucial component of the NHS Stop 
Smoking Services as smokers need to be given a choice of treatment options. 
As both studies took place within the English smoking cessation services, they 
are directly applicable to the target population. 
Evidence statement 2.8 
Information on how the site/setting impacts on the effectiveness of smoking 
cessation interventions is limited. Evidence from a 2 (++) study indicates that 
the location of treatment may indirectly influence the effectiveness of smoking 
cessation interventions.    
As this study took place within the UK smoking cessation services, it is directly 
applicable to the target population.  
Evidence statement 2.9 
Two 1 (++) systematic reviews provide strong evidence that smoking 
cessation interventions among inpatients can be effective in creating modest 
to substantial increases in CO-validated smoking cessation rates up to 12 
months in this population. Findings from four more recent 1 (++) studies and 
one 1 (+) study are mixed; however, on the whole they indicate that 
interventions with at least 2 months post-discharge telephone follow-up are 
more likely to be successful than programmes of short duration. The majority 
of the studies took place outside of the UK in a wide range of countries 
including Australia, Canada, the USA and Norway. However, it is likely that 
their findings are applicable to the UK, given the broad similarities in these 
populations.    
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Evidence statement 2.17 
The evidence on how readily black and minority ethnic groups are accessing 
the stop smoking services is inconclusive. Five 3 (-) studies appear to 
demonstrate that black and minority groups on the whole are accessing stop 
smoking services in proportion with their representation within the total 
population; however, a high level of missing data undermines the 
conclusiveness of the available statistics. Moreover, indicative evidence raises 
some doubts about how readily black and minority ethnic groups are 
accessing NHS Stop Smoking Services. As these studies were conducted on 
the smoking cessation services in the UK, their results are directly applicable 
to the population under study. 
Evidence statement 2.18 
There is no direct evidence on how minority ethnic status intersects with 
gender in relation to smoking and quit status in the context of interventions 
delivered through the stop smoking services. Background evidence indicates 
that females from black and minority ethnic groups appear to be less likely 
(significantly less likely in South Asian communities) to smoke than males. 
However, given the stigma that attaches to female smoking in many minority 
ethnic groups (especially South Asians), it is probable that smoking rates 
among minority ethnic females are underreported. Among Bangladeshi 
women in particular, although self-reported smoking prevalence is low, use of 
tobacco itself is very high (over 25%).       
Evidence statement 2.19 
There is no direct evidence on how minority ethnic status intersects with social 
class in relation to smoking and quit status in the context of interventions 
delivered through the stop smoking services. Overall, background evidence 
indicates that for the most part, smoking in black and minority ethnic groups 
does not appear to be connected with social class, except in relation to 
Bangladeshi males – whose high smoking rates may be partly accounted for 
by the relative levels of social disadvantage in this ethnic group. 
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Evidence statement 2.20 
The evidence on how successful black and minority ethnic groups are in 
quitting smoking through the stop smoking services is inconclusive. One 2 (+) 
study found that CO-validated quitting success at 4 weeks did not vary by 
ethnicity. However, because of the small numbers of people from black and 
minority ethnic groups in the study, interpretation of their results is difficult. As 
this study was conducted on the smoking cessation services in the UK, its 
results are directly applicable to the population under study. 
Evidence statement 2.21 
There is no direct evidence on how culturally appropriate the NHS Stop 
Smoking Services are, although it seems to be the case that there are 
relatively few programmes overall that cater to ethnic minorities – in most 
cases people from these groups are incorporated into the broader NHS. 
However, it appears that smoking cessation interventions tailored for minority 
ethnic groups can achieve high levels of success. 
Evidence statement 2.22 
Five 3 (-) bulletins, one 2 (+) and one 2 (++) study provide a body of evidence 
that between 23% and 51% of pregnant women self-report as successful 
quitters at 4 weeks through the NHS Stop Smoking Services. However, given 
the unique challenges that pregnant smokers face, the utility of 4-week quit 
rates as a measure of service effectiveness is questionable. As all seven 
studies took place within smoking cessation services in the UK, they are 
directly applicable to the target population. 
Evidence statement 2.23 
Background evidence indicates that there are numerous barriers to recruiting 
pregnant women into smoking cessation programmes. One of the most 
fundamental barriers to recruitment is the problem of misreport among 
pregnant smokers – which indicates the importance of biochemically 
validating smoking status. Healthcare professionals are also often unwilling to 
address smoking with their pregnant clients in the fear that it will jeopardise 
their relationship with the clients. 
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Evidence statement 2.25 
Three 2 (++) studies and one 2 (+) study provide a body of evidence that the 
NHS Stop Smoking Services have been effective overall in reaching routine 
and manual groups. However, one of these studies reports that there is 
variation within regional services, and some strategic health authorities have 
been less successful in reaching deprived smokers than others. As all four 
studies took place within the English smoking cessation services, they are 
directly applicable to the target population. 
Evidence statement 2.26 
Six 3 (-) bulletins, one 2 (-) study, two 2 (+) studies and three 2 (++) studies 
provide a consistent body of evidence that people from routine and manual 
groups are less successful in quitting successfully (based on both self-report 
and CO validation) at 4 weeks than other smokers. As all twelve studies took 
place within the English smoking cessation services, they are directly 
applicable to the target population. 
Evidence statement 2.27 
One 2 (+) study found that NHS stop smoking services are making a modest 
contribution to reducing smoking-related inequalities in health in England. As 
the study took place within the English smoking cessation services, it is 
directly applicable to the target population. 
Evidence statement 2.28 
Background evidence shows that smokers from routine and manual groups 
face numerous social and economic barriers that may inhibit their ability to 
quit. In many areas of deprivation, smoking is perceived as the norm and 
there is no culture of quitting. Moreover, those deprived smokers who are 
willing to quit may have little knowledge about the effectiveness of smoking 
cessation interventions and may also find it difficult to attend sessions. 
Evidence statement 2.29 
Background evidence shows that smokers from routine and manual groups 
are often more highly addicted, have been smoking since a young age, and 
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smoke more cigarettes per week compared to professional workers, which is 
a key factor in explaining the lower cessation rates achieved by the NHS Stop 
Smoking Services in deprived areas. 
Evidence statement 2.30 
According to a 2 (-) study, more flexible modes of delivery help to make 
smoking cessation interventions more accessible for people from deprived 
groups and produce 12 month self-reported quit rates of 16% – which is 
comparable with the long-term effectiveness of the NHS Stop Smoking 
Services more broadly.    
Evidence statement 2.31 
Although up to 80% of prisoners in UK correctional facilities smoke, according 
to a recent 2 (++) report, overall a relatively small proportion of smokers (less 
than 10%) access smoking cessation support while in prison. However, 
prisoners can achieve CO-validated 4-week quit rates of over 40%, although 
there appear to be substantial differences in the success rates of different 
prisons. As this study looks at the effectiveness of the smoking cessation 
services in UK prisons, it is directly applicable to the target population. 
Evidence statement 2.32 
Smoking is a central feature of prison life and provides relief from boredom, 
the stressful environment as well as facilitating group membership. Therefore, 
prisoners face unique problems when making a quit attempt because of the 
endemic levels of smoking, the lack of opportunities for distraction from 
cravings and negative attitudes to cessation among staff and fellow prisoners. 
Despite these barriers, a number of prisoners recognise the negative aspects 
of smoking, including its health and financial costs and evidence indicates that 
up to 50% of smokers in prison want help in quitting smoking.   
Evidence statement 2.33 
Although it appears that rates of smoking are particularly high among people 
in mental health institutions in the UK, there is no available information on how 
effective smoking cessation support is in this setting. 
  
 75 
Evidence statement 2.34 
People with mental illnesses in institutional settings face a variety of barriers 
in accessing services and quitting smoking. Smoking cessation in this setting 
can be complicated by factors such as physiological vulnerability to nicotine 
addiction, the fact that nicotine may reduce the side effects of some 
medications, the positive effects of nicotine on the brain, and the use of 
cigarettes as a behavioural reward and lack of access to cessation support.    
Evidence statement 3.1 
Overall, it appears that workplace interventions in the context of 
‘environmental support’ (workplace smoking restrictions and educational 
campaigns) are effective in facilitating smoking cessation. One 2 (+) American 
study found that a smoking cessation programme delivered in the context of a 
workplace smoking ban and educational campaign produced long-term 
success rates similar to smoking cessation programmes more broadly. 
Another 1 (-) American study found that environmental support may increase 
the success of workplace interventions, at least in the short term.  Two 2 (-) 
studies have identified Allen Carr workplace seminars to be an effective 
means of facilitating smoking cessation in the workplace. Online smoking 
cessation programmes have also been highlighted in a 4 (+) report as a 
potentially effective way of facilitating smoking cessation in the workplace. 
However, evidence on the effectiveness of these interventions types is 
presently weak and further research is needed to determine their 
effectiveness. 
Evidence statement 3.2 
A 1 (++) systematic review and a 1 (+) meta-analysis of the available 
international literature indicates that the most effective smoking cessation 
interventions in workplace settings are those interventions that have proven 
effectiveness more broadly. There is strong evidence that group therapy, 
individual counselling and pharmacological treatments all have an effect in 
facilitating smoking cessation. However, both reviews failed to identify effects 
due to particular intervention type. There is also evidence that minimal 
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interventions including brief advice from a health professional are effective.  
Self-help manuals appear to be less effective, although there is limited 
evidence that interventions tailored to the individual have some effect. 
Evidence statement 3.3 
Two 1 (++) systematic reviews of international studies indicate that financial 
incentives are most commonly used by employers to encourage employee 
compliance with smokefree workplace policies and the uptake of smoking 
cessation support. While the addition of incentives does not appear to 
increase the quit rates of smoking cessation interventions in the workplace, 
there is some evidence that such incentives do improve recruitment rates into 
worksite cessation programmes, which may lead to higher absolute numbers 
of successful quitters in the long term. There is also some evidence that 
incentives may delay relapse to smoking, even if they don’t prevent it 
altogether. 
Evidence statement 3.10 
A 1 (++) systematic review indicates that workplace interventions may have 
the potential for higher participation rates than other contexts, and also 
provide the opportunity to access smokers who would otherwise not be 
accessible. These represent significant potential outcomes of workplace 
interventions.  
Evidence statement 3.20 
Workplace smoking bans and smokefree legislation should be carefully 
planned, include the input of smokers, and be accompanied by provision of 
help and support for smokers. Public support for bans and legislation can be 
strengthened by using media campaigns to inform the public about the 
adverse health effects of passive smoking and by treating the issue as a 
worker protection law rather than a consumer protection law. An effort should 
be made to understand diversity, and materials and messages should be 
culturally appropriate. An adequate revenue base is crucial to support the 
implementation of legislation. 
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Evidence statement 4.3 
There is level 2 (+) evidence, probably relevant to the UK population, 
indicating that the addition (to a web-based self-help style smoking cessation 
intervention) of an automated email educational messaging system was 
associated with an increase in the 30-day intent to treat quit rates (7.5% vs. 
13.6%, p = 0.035). 
Evidence statement 4.8 
There is evidence from a level 1&2 (+) review, probably relevant to the UK 
population, that multi-channel mass media campaigns (combined with other 
interventions) are effective in increasing tobacco use cessation. Cessation 
rates in the intervention groups ranged from 3.9% (confirmed) to 50% (self-
reported), with a median of 7% in follow-up periods of 6 months to 5 years. 
There is evidence from another review (level 2 [-]), possibly relevant to the UK 
population, that shows that media campaigns and concurrently implemented 
tobacco control programmes (or policies) are associated with a reduction in 
the net smoking prevalence of between 6–12%. Other level 2 (-) and 3 
evidence reported either inconclusive results, or in the case of a Dutch 
campaign (3), estimated the follow-up point prevalence abstinence rate 
attributable to the campaign as 4.5% after control for test effects and secular 
trends. There is level 1 (+) evidence, probably relevant to UK workplaces, 
which found that adding peer group support and lottery incentives to mass 
media-based self-help interventions led to abstinence levels of 19.5% in the 
control group compared with 30% in the intervention group at 2 years.      
Evidence statement 4.10 
There is level 1 (++) evidence, probably relevant to the UK population, which 
found that a web-based smoking cessation programme using more extensive 
information on coping strategies and health risks is more effective at the 
contemplation stage than shorter programmes with less health-related 
information at 3 months. There were statistically significant differences in quit 
rates in smokers using the more extensive programme (OR=1.54, 95% CI: 
1.18-2.02, p=.002). There is level 1 (+) evidence, probably relevant to the UK 
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population, that a behavioural intervention for smoking cessation delivered via 
an Internet website can achieve a quit rate of 12.3% at 3 months (compared 
with 5% of controls). There is level 2 (-) and 3 evidence, probably relevant to 
the UK population, which reported that other web-based smoking cessation 
sites can achieve quit rates of up to 18%. 
Evidence statement 4.11 
There is level 1 (++) evidence, probably relevant to the UK population, that a 
text message-based intervention can increase smoking cessation rates (28% 
vs 13%, RR 2.20, 95% CI: 1.79 to 2.70, p < 0.0001) at 6 weeks. 
Evidence statement 4.21 
There is level 2 (-) evidence, probably relevant to UK college and university 
students, which shows a positive effect of an Internet-based smoking 
cessation intervention on smoking cessation. There is level 3 evidence, 
possibly relevant to young people in the UK, that reports reductions in 
smoking and quit attempts in rural teens after using an Internet-based virtual 
reality ’world‘ for smoking cessation. There is level 3 evidence, probably 
relevant to young people in the UK that an integrated web and text-messaging 
programme may result in quit rates of 17%. 
Evidence statement 4.24 
There is level 2 (-) and 3 evidence, probably relevant to the UK population, 
that posters or printed media can be an effective way of increasing awareness 
of campaigns. No studies were identified which evaluated the effectiveness of 
interventions of different duration. 
Evidence statement 4.26 
There is level 1 (+) evidence, probably relevant to UK workplaces, that 
television message recall is associated with increased smoking cessation 
rates. There is level 3 evidence, probably relevant to the UK, which indicates 
that the more TV episodes watched or recalled, the higher the incidence of 
self-reported quitting or abstinence from smoking. There is level 3 evidence, 
probably relevant to the UK, which indicates that the effectiveness of a web-
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based cessation programme is increased according to the amount of 
exposure to educational materials. There is level 3 evidence, probably 
relevant to the UK adult population, that the relative risk for quitting was 
estimated to be 10% higher for every 5000 units of exposure to state anti-
tobacco television advertising over a 2 year period. However, these results did 
not achieve statistical significance. There is level 2 (+) evidence, directly 
relevant to the UK population, that varying the intensity of TV adverts does not 
have an effect on smoking cessation. 
Evidence statement 4.27 
There is level 2 (-) evidence, which is probably relevant to the UK population, 
which suggests that advertisements depicting suffering as a result of tobacco 
use may be instrumental in promoting cessation or reinforcing the decision to 
quit. There is level 3 evidence, probably relevant to UK teens, that indicates 
that dissonance-arousing messages specifically targeting girls can have 
positive short-term effects on quit rates. There is also level 3 evidence that 
shows that graphic mass media messages about the negative consequences 
of smoking among adults has a positive effect on quit attempts among young 
people (18% of smokers in the sample attempted to quit [95% CI: 14% to 
22%]). Finally, there is level 2 (-) evidence providing insufficient evidence that 
longer positive messages are less effective than short, negative messages. 
Evidence statement 4.28 
Four studies (both qualitative and quantitative) evaluated outcomes such as 
the acceptability and usage of web-based interventions. One qualitative study 
reported that participants sought online smoking cessation resources for 
reasons of convenience, timeliness, anonymity and because their current 
information needs were unmet. Another level 1 (+) study, probably relevant to 
the UK population, found that the optional sections of an intervention most 
used/viewed were setting a quit date, and the descriptions of pharmacological 
aids. A level 2 (-) study reported that the ‘Ask an expert’ section was rated 
most highly. The fourth study (level 2 [-]) reported that the intervention helped 
to raise consciousness about quitting, encouraged behavioural goals, 
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provided stages of change feedback, and offered interactivity in presenting 
information and strategies about quitting. No studies were identified which 
evaluated the views of those delivering the intervention. No studies were 
identified which assessed inequalities of access. 
Evidence statement 5.1 
Two 1 (+) studies found that reactive quitlines improved abstinence rates over 
the distribution of self-help materials alone. Three 2 (+) studies provide further 
support for the effectiveness of quitlines, and found self-report 12-month 
abstinence rates of between 8.2% and 15.6%. As two of these studies took 
place in the UK, and results are broadly consistent across studies, these 
findings are likely to be directly applicable to a UK setting. 
Evidence statement 5.3 
There is strong evidence from a 1 (++) Cochrane Review and one 1 (+) meta-
analysis that proactive telephone counselling has a modest effect on smoking 
cessation. As these reviews are international in scope their findings are likely 
to be applicable to a UK setting. 
Evidence statement 5.4 
Although there is limited available evidence regarding the comparative 
effectiveness of proactive and reactive quitlines, one 2 (+) study found that 
self-reported 12-month abstinence rates were somewhat higher for proactive 
compared with reactive support – although the difference was not statistically 
significant. Although the study was conducted in Northern Europe, its results 
are likely to be broadly applicable to a UK setting. 
Evidence statement 5.13 
Further research needs to be conducted into the effectiveness of telephone 
counselling for minority ethnic groups as the existing limited evidence is 
inconclusive. A 1 (-) study found that the addition of telephone counselling did 
not improve the effectiveness of a smoking cessation intervention aimed at 
African American smokers above and beyond a provider-prompted 
intervention and self-help materials. A second 1 (+) study found that 
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enhanced telephone counselling for Hispanic smokers did significantly 
increase abstinence rates, when demographic and smoking-related variables 
were controlled. As these studies were conducted in the USA, which has a 
different ethnic composition to the UK, their results are not directly applicable 
to a UK setting. 
Evidence statement 5.17 
Although further research is needed regarding the cost-effectiveness of 
quitlines, a cost-effectiveness analysis of the Swedish national quitline (+ 
rating) found it to be particularly cost effective: the researchers calculate the 
cost per year of life saved as equivalent to USD 311–401. A 2 (+) study of the 
cost of quitlines also deems them to represent a very modest expense for 
governments that provide these services, although a 3 (+) case report warns 
that services need to be marketed to large populations to be effective. 
Although these studies were conducted outside of the UK, the costs of 
running a national quitline are likely to be similar from one country to the next.  
Therefore, their findings are likely to be broadly applicable to a UK setting. 
Additional evidence 
Gutierrez (2007) Mass media interventions to stimulate and promote smoking 
cessation. (Expert paper) Available from: www.nice.org.uk/PH010 
NICE (2002) Guidance on the use of nicotine replacement therapy (NRT) and 
bupropion for smoking cessation. NICE technology appraisal 39. Available 
from: www.nice.org.uk/TA039 
NICE (2007) Varenicline for smoking cessation. NICE technology appraisal 
123.  Available from: www.nice.org.uk/TA123 
University of Birmingham (2006) Clinical and cost-effectiveness of nicotine 
replacement therapy for new licensed indications and combination therapy: a 
summary of best evidence. Available from: www.nice.org.uk/PH010 
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Wang et al. (2006) Cut down to quit with nicotine replacement therapies 
(NRT) in smoking cessation: systematic review of effectiveness and economic 
analysis. Available from: www.nice.org.uk/PH010 
Cost-effectiveness evidence  
Overall, brief advice, individual behavioural counselling, group behaviour 
therapy, pharmacotherapies, self-help materials, telephone counselling and 
quitlines were cost effective compared with no intervention.  
Group counselling was more cost effective than individual counselling. Brief 
advice and more intensive counselling, when combined with either NRT or 
bupropion, was more cost effective than either advice or counselling provided 
on its own. NRT and bupropion, combined with advice or counselling, was 
more cost effective than either NRT or bupropion provided on its own. 
Varenicline was cost effective compared with either bupropion, NRT or 
placebo.  
The nicotine-assisted reduction to stop (NARS) approach, supported by 
intensive counselling, was cost effective for people who were initially unwilling 
to quit smoking (or unwilling to quit without cutting down first) compared with 
counselling on its own. This estimate assumes that those undertaking CDTQ 
would not have made an abrupt quit attempt: it is generally more cost effective 
for people to attempt quitting abruptly rather than make an initial attempt by 
first cutting down using CDTQ.  
No-one can ever be sure in advance whether a mass media campaign will 
work, but if such a campaign succeeds by encouraging even a comparatively 
small number of people to stop smoking, it will be cost effective. The more 
successful campaigns will be extremely cost effective. 
Methods of assisting pregnant women to quit smoking are cost effective if the 
women do not return to smoking after the birth of the baby. Insufficient 
evidence was available to determine whether home visits by specialist stop 
smoking professionals were cost effective compared with attending stop 
smoking clinics, using NRT or attempting to quit without assistance.   
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Fieldwork findings  
Fieldwork aimed to test the relevance, usefulness and the feasibility of 
implementing the recommendations and the findings were considered by the 
PDG in developing the final recommendations. For details, go to the fieldwork 
section in appendix B and www.nice.org.uk/PH010 
Fieldwork participants who work with people who smoke and other tobacco 
users were generally very positive about the recommendations and their 
potential to improve the provision of smoking cessation services and help 
people to stop smoking. Many stated that the recommendations were easy to 
read and understand. They also said they gave them a clear understanding 
about who to target and the types of smoking cessation products and services 
that are effective. They welcomed the fact that the recommendations were 
evidence-based. 
PCT staff hoped the recommendations would encourage decision-makers to 
provide them with the resources they need to deliver an effective, responsive, 
smoking cessation service. 
Although participants agreed that all healthcare professionals should be able 
to offer people brief advice on smoking and, where necessary, refer them to 
smoking cessation services, some felt this would not be feasible within the 
available resources. In addition, some healthcare professionals, particularly 
hospital staff and dentists, questioned the value of involving them in brief 
interventions and referrals. However, smoking cessation practitioners thought 
it was helpful that the guidance encouraged hospital staff to provide smoking 
cessation advice and make referrals. 
PCT staff and practitioners who are involved in workplace stop-smoking 
schemes hope that this guidance will help expand this work. 
Most participants agreed that smoking cessation advisers should be trained 
and should receive further training on a continuing basis, but relatively few 
knew whether the training they had received complied with national standards.  
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Appendix D: gaps in the evidence 
The PDG identified a number of gaps in the evidence related to the 
programmes under examination, based on an assessment of the evidence. 
These gaps are set out below. 
1. Data routinely collected by the NHS Stop Smoking Services are not 
particularly helpful as an aid to improving the service. For example, 
although reducing prevalence among people in routine and manual groups 
is a priority, information on occupation is not part of the minimum data set 
required by the DH.  
2. Certain groups, such as pregnant women, routine and manual workers 
and people living in institutions, face substantial barriers to quitting 
smoking. Research is needed to provide a fuller picture of the 
effectiveness and cost effectiveness of smoking cessation services for 
these groups. In particular, the cost effectiveness of home visits by 
specialist stop smoking professionals for pregnant women who smoke 
should be compared with the women attending stop smoking clinics, 
using NRT or attempting to quit without assistance.   
3. Although some commercial smoking cessation treatments may be 
effective, there is little or no evidence of effectiveness from high quality, 
comparative trials. 
4. New media such as text messaging and podcasts are potentially effective 
in delivering personalised advice to people who smoke. However, more 
published evidence of their longer-term impact is needed. 
5. More information is needed on the impact of mass media smoking 
cessation messages on people who smoke who are pregnant, socio-
economically disadvantaged or from a minority ethnic group.  
6. More information is needed about both the cost-effectiveness of 
workplace interventions and their long-term effectiveness, particularly in 
the context of widespread smoking restrictions. 
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7. More information is needed about the long-term benefits to employers of 
providing workplace smoking cessation support.    
8. More information is needed on the cost effectiveness of using specially 
trained midwives to deliver smoking cessation advice to pregnant women 
who smoke compared with: 
• home visits by specialist stop smoking professionals  
• attending stop smoking clinics 
• attempting to quit without assistance. 
The Group made six recommendations for research. These are listed in 
section 6. 
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Appendix E: supporting documents 
Supporting documents are available from the NICE website 
(www.nice.org.uk/PH010). These include the following. 
• Reviews of effectiveness 
− Review 1: ‘Rapid review of non NHS treatments of smoking 
cessation’  
− Review 2: ‘The effectiveness of National Health Service 
intensive treatments for smoking cessation in England’ 
− Review 3: ‘Workplace policies for smoking cessation’ 
− Review 4: ‘A review of the effectiveness of mass media 
interventions which both encourage quit attempts and 
reinforce current and recent attempts to quit smoking’  
− Review 5: ‘The impact of quitlines on smoking cessation’ 
− Expert paper: ‘Mass media interventions to stimulate and 
promote smoking cessation’. 
• Economic evaluations  
− ‘A rapid review of the cost effectiveness of non-National 
Health Service treatments for smoking cessation in England’ 
− ‘A rapid review of the cost effectiveness of National Health 
Service treatments for smoking cessation in England’  
− ‘A rapid review of the cost effectiveness of workplace policies 
for smoking cessation in England’  
− ’A rapid review of: the cost effectiveness of mass media 
interventions for smoking cessation in England‘.  
• Economic analyses 
− ‘Cost-effectiveness of interventions for smoking cessation’ 
− ‘Cost-effectiveness of interventions for smoking cessation: 
mass media’ 
− ‘Cost-impact analysis of interventions of interventions for 
smoking cessation aimed at pregnant women’.  
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• Reviews for the update of technology appraisal guidance 39  
− ‘Cut down to quit with nicotine replacement therapies (NRT) in 
smoking cessation: systematic review of effectiveness and 
economic analysis’  
− ‘Clinical and cost-effectiveness of nicotine replacement 
therapy for new licensed indications and combination therapy: 
a summary of best evidence’.  
• A quick reference guide (QRG) for professionals whose remit includes 
public health an for interested members of the public. This is also available 
from NICE publications on 0845 003 7783 or email 
publications@nice.org.uk and quote: N1478.  
For information on how NICE public health guidance is developed, see: 
• ‘Methods for development of NICE public health guidance’ available from: 
www.nice.org.uk/phmethods 
• ‘The public health guidance development process: an overview for 
stakeholders including public health practitioners, policy makers and the 
public’ available from: www.nice.org.uk/phprocess 
